{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T21:42:14Z","timestamp":1791322934010,"version":"4.3.1"},"reference-count":409,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1016\/j.intimp.2011.05.008","type":"journal-article","created":{"date-parts":[[2011,5,28]],"date-time":"2011-05-28T12:37:28Z","timestamp":1306586248000},"page":"1464-1488","source":"Crossref","is-referenced-by-count":105,"title":["Vaccine candidates for leishmaniasis: A review"],"prefix":"10.1016","volume":"11","author":[{"given":"Rajeev","family":"Nagill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukhbir","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2011.05.008_bb0005","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1046\/j.1365-2915.2001.00294.x","article-title":"Phlebotomine sandfly responses to carbon dioxide and human odour in the field","volume":"15","author":"Pinto","year":"2001","journal-title":"Med Vet Entomol"},{"key":"10.1016\/j.intimp.2011.05.008_bb0010","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1136\/bmj.326.7385.377","article-title":"Leishmaniasis: new approaches to disease control","volume":"326","author":"Davies","year":"2003","journal-title":"BMJ"},{"issue":"7025","key":"10.1016\/j.intimp.2011.05.008_bb0015","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1136\/bmj.312.7025.247","article-title":"Tropical medicine for the 21st century. Tropical medicine should be concerned with medical problems endemic to the tropics","volume":"312","author":"Bryceson","year":"1996","journal-title":"BMJ"},{"key":"10.1016\/j.intimp.2011.05.008_bb0020","series-title":"The granulomatous diseases","first-page":"212","article-title":"Leishmaniasis","author":"Baker","year":"1999"},{"key":"10.1016\/j.intimp.2011.05.008_bb0025","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1136\/pgmj.2006.047340","article-title":"Leishmaniasis","volume":"82","author":"Piscopo","year":"2006","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.intimp.2011.05.008_bb0030","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1136\/bmj.1.5339.1208","article-title":"Development of kala-azar in man after inoculation with a Leishmania from a Kenyo sandfly","volume":"1","author":"Manson-Bahr","year":"1963","journal-title":"BMJ"},{"key":"10.1016\/j.intimp.2011.05.008_bb0035","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.cimid.2004.03.004","article-title":"Leishmaniasis: current situation and new perspectives","volume":"27","author":"Desjeux","year":"2004","journal-title":"Comp Immunol Microbiol Infect Dis"},{"issue":"Suppl. 1","key":"10.1016\/j.intimp.2011.05.008_bb0040","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/S0035-9203(01)90218-4","article-title":"Leishmaniasis in Sudan. Visceral leishmaniasis","volume":"95","author":"Zijlstra","year":"2001","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.intimp.2011.05.008_bb0045","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0035-9203(03)80047-0","volume":"97","author":"Ritmeijer","year":"2003","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.intimp.2011.05.008_bb0050","doi-asserted-by":"crossref","first-page":"389","DOI":"10.4314\/eamj.v83i7.9451","article-title":"Visceral leishmaniasis in Northern Ethiopia","volume":"83","author":"Haile","year":"2006","journal-title":"East Afr Med J"},{"key":"10.1016\/j.intimp.2011.05.008_bb0055","doi-asserted-by":"crossref","first-page":"275","DOI":"10.4269\/ajtmh.2007.77.275","article-title":"Kala-azar outbreak in Libo Kemkem, Ethiopia: epidemiologic and parasitologic assessment","volume":"77","author":"Alvar","year":"2007","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.intimp.2011.05.008_bb0060","first-page":"105","article-title":"Can visceral leishmaniasis eliminated from Asia?","volume":"45","author":"Joshi","year":"2008","journal-title":"J Vector Borne Dis"},{"key":"10.1016\/j.intimp.2011.05.008_bb0065","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S1473-3099(07)70209-8","article-title":"Cutaneous leishmaniasis","volume":"7","author":"Reithinger","year":"2007","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.intimp.2011.05.008_bb0070","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/0738-081X(96)00058-2","article-title":"Cutaneous leishmaniasis: clinical aspects","volume":"14","author":"Dowlati","year":"1996","journal-title":"Clin Dermatol"},{"issue":"12","key":"10.1016\/j.intimp.2011.05.008_bb0075","doi-asserted-by":"crossref","first-page":"E69","DOI":"10.1086\/340526","article-title":"Failure of early treatment of cutaneous leishmaniasis in preventing the development of an ulcer","volume":"34","author":"Machado","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.intimp.2011.05.008_bb0080","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.idc.2004.11.005","article-title":"Cutaneous leishmaniasis in the returning traveler","volume":"19","author":"Magill","year":"2005","journal-title":"Infect Dis Clin N Am"},{"key":"10.1016\/j.intimp.2011.05.008_bb0085","first-page":"357","article-title":"Leishmania\/HIV co-infections in the second decade","volume":"123","author":"Cruz","year":"2006","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.intimp.2011.05.008_bb0090","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1590\/S0102-311X2000000400013","article-title":"The epidemiology and control of leishmaniasis in Andean countries","volume":"16","author":"Davies","year":"2000","journal-title":"Cad Saude Publica"},{"key":"10.1016\/j.intimp.2011.05.008_bb0095","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/0035-9203(86)90243-9","article-title":"Mucosal leishmaniasis (\u201cespundia\u201d Escomel, 1911)","volume":"80","author":"Marsden","year":"1986","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.intimp.2011.05.008_bb0100","first-page":"73","article-title":"Mucosal leishmaniasis caused by Leishmania tropica in Saudi Arabia","volume":"25","author":"Morsy","year":"1995","journal-title":"J Egypt Soc Parasitol"},{"key":"10.1016\/j.intimp.2011.05.008_bb0105","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/01.md.0000076009.64510.b8","article-title":"Localized mucosal leishmaniasis due to Leishmania infantum: clinical and microbiologic findings in 31 patients","volume":"82","author":"Aliaga","year":"2003","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.intimp.2011.05.008_bb0110","first-page":"27","article-title":"Mucosal localization of leishmaniasis in Tunisia: 5 cases","volume":"130","author":"Kharfi","year":"2003","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.intimp.2011.05.008_bb0115","series-title":"Pioneer of tropical medicine","isbn-type":"print","author":"Gavron","year":"1997","ISBN":"https:\/\/id.crossref.org\/isbn\/0866890459"},{"key":"10.1016\/j.intimp.2011.05.008_bb0120","doi-asserted-by":"crossref","first-page":"4714","DOI":"10.1128\/IAI.73.8.4714-4722.2005","article-title":"Conditions influencing the efficacy of vaccination with live organisms against Leishmania major infection","volume":"73","author":"Tabbara","year":"2005","journal-title":"Infect Immun"},{"issue":"3","key":"10.1016\/j.intimp.2011.05.008_bb0125","first-page":"423","article-title":"Leishmaniasis vaccine candidates for development: a global overview","volume":"123","author":"Khamesipour","year":"2006","journal-title":"Indian J Med Res"},{"issue":"Suppl.1","key":"10.1016\/j.intimp.2011.05.008_bb0130","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1080\/00034983.1995.11813017","article-title":"Vaccines against leishmaniasis","volume":"89","author":"Modabber","year":"1995","journal-title":"Ann Trop Med Parasitol"},{"key":"10.1016\/j.intimp.2011.05.008_bb0135","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1017\/S0031182006001831","article-title":"Leishmania vaccines: progress and problems","volume":"133","author":"Kedzierski","year":"2006","journal-title":"Parasitology"},{"key":"10.1016\/j.intimp.2011.05.008_bb0140","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/icb.1984.14","article-title":"Vaccination against cutaneous leishmaniasis in mice using nonpathogenic cloned promastigotes of Leishmania major and importance of route of injection","volume":"62","author":"Mitchell","year":"1984","journal-title":"Aust J Exp Biol Med Sci"},{"key":"10.1016\/j.intimp.2011.05.008_bb0145","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0008-8749(85)90081-4","article-title":"Immunization of susceptible BALB\/c mice against Leishmania braziliensis. II. Use of temperature-sensitive avirulent clones of parasite for vaccination purposes","volume":"94","author":"Gorczynski","year":"1985","journal-title":"Cell Immunol"},{"key":"10.1016\/j.intimp.2011.05.008_bb0150","first-page":"35","article-title":"Vaccine development against cutaneous leishmaniasis. Subcutaneous administration of radioattenuated parasites protects CBA mice against virulent Leishmania major challenge","volume":"152","author":"Rivier","year":"1993","journal-title":"Mol Biochem Parasitol"},{"key":"10.1016\/j.intimp.2011.05.008_bb0155","doi-asserted-by":"crossref","first-page":"5205","DOI":"10.1128\/IAI.61.12.5205-5213.1993","article-title":"An avirulent lipophosphoglycan-deficient Leishmania major clone induces CD4+ T cells which protect susceptible BALB\/c mice against infection with virulent L. major","volume":"61","author":"Kimsey","year":"1993","journal-title":"Infect Immun"},{"key":"10.1016\/j.intimp.2011.05.008_bb0160","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1086\/374783","article-title":"Leishmania mexicana and Leishmania major: attenuation of wild-type parasites and vaccination with the attenuated lines","volume":"187","author":"Daneshvar","year":"2003","journal-title":"J Infect Dis"},{"key":"10.1016\/j.intimp.2011.05.008_bb0165","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.4049\/jimmunol.166.3.1921","article-title":"Protective immunity against the protozoan Leishmania chagasi is induced by subclinical cutaneous infection with virulent but not avirulent organisms","volume":"166","author":"Streit","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.intimp.2011.05.008_bb0170","doi-asserted-by":"crossref","first-page":"10267","DOI":"10.1073\/pnas.92.22.10267","article-title":"Development of a safe live Leishmania vaccine line by gene replacement","volume":"92","author":"Titus","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.intimp.2011.05.008_bb0175","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1590\/S0074-02761999000400011","article-title":"A dhfr-ts Leishmania major knockout mutant cross-protects against Leishmania amazonensis","volume":"94","author":"Veras","year":"1999","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"10.1016\/j.intimp.2011.05.008_bb0180","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1590\/S0074-02762002000700019","article-title":"Study of the safety, immunogenicity and efficacy of attenuated and killed Leishmania major vaccines in a rhesus monkey (Macaca mulatta) model of the human disease","volume":"97","author":"Amaral","year":"2002","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"10.1016\/j.intimp.2011.05.008_bb0185","doi-asserted-by":"crossref","first-page":"6967","DOI":"10.4049\/jimmunol.167.12.6967","article-title":"Immune elimination of Leishmania major in mice: implications for immune memory, vaccination, and reactivation disease","volume":"167","author":"Uzonna","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.intimp.2011.05.008_bb0190","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.4049\/jimmunol.172.6.3793","article-title":"Vaccination with phosphoglycan-deficient Leishmania major protects highly susceptible mice from virulent challenge without inducing a strong Th1 response","volume":"172","author":"Uzonna","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.intimp.2011.05.008_bb0195","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1126\/science.1087499","article-title":"Persistence without pathology in phosphoglycan deficient Leishmania major","volume":"301","author":"Spath","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.intimp.2011.05.008_bb0200","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1128\/IAI.74.1.777-780.2006","article-title":"Immunization with persistent attenuated (delta) lpg2 Leishmania major parasites requires adjuvant to provide protective immunity in C57BL\/6 mice","volume":"74","author":"Kebaier","year":"2006","journal-title":"Infect Immun"},{"key":"10.1016\/j.intimp.2011.05.008_bb0205","doi-asserted-by":"crossref","first-page":"4988","DOI":"10.1074\/jbc.M008030200","article-title":"Phosphoglycan repeat-deficient Leishmania mexicana parasites remain infectious to macrophages and mice","volume":"276","author":"Ilg","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.intimp.2011.05.008_bb0210","doi-asserted-by":"crossref","first-page":"3622","DOI":"10.1128\/IAI.72.6.3622-3627.2004","article-title":"Identification of a compensatory mutant (lpg2-REV) of Leishmania major able to survive as amastigotes within macrophages without LPG2-dependent glycoconjugates and its significance to virulence and immunization strategies","volume":"72","author":"Spath","year":"2004","journal-title":"Infect Immun"},{"key":"10.1016\/j.intimp.2011.05.008_bb0215","doi-asserted-by":"crossref","first-page":"6794","DOI":"10.4049\/jimmunol.161.12.6794","article-title":"Leishmania mexicana cysteine proteinase-deficient mutants have attenuated virulence for mice and potentiate a Th1 response","volume":"161","author":"Alexander","year":"1998","journal-title":"J Immunol"},{"key":"10.1016\/j.intimp.2011.05.008_bb0220","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1016\/j.vaccine.2005.05.045","article-title":"Pathogenicity and protective immunogenicity of cysteine proteinase-deficient mutants of Leishmania mexicana in non-murine models","volume":"24","author":"Saravia","year":"2006","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.intimp.2011.05.008_bb0225","doi-asserted-by":"crossref","first-page":"3901","DOI":"10.1073\/pnas.0630165100","article-title":"Genetic characterization of glucose transporter function in Leishmania mexicana","volume":"100","author":"Burchmore","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.intimp.2011.05.008_bb0230","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.molbiopara.2007.01.010","article-title":"Phenotypic characterization of a glucose transporter null mutant in Leishmania mexicana","volume":"153","author":"Rodriguez-Contreras","year":"2007","journal-title":"Mol Biochem Parasitol"},{"key":"10.1016\/j.intimp.2011.05.008_bb0235","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1046\/j.1365-2958.1998.00689.x","article-title":"Targeted gene deletion of Leishmania major genes encoding developmental stage-specific leishmanolysin (GP63)","volume":"27","author":"Joshi","year":"1998","journal-title":"Mol Microbiol"},{"key":"10.1016\/j.intimp.2011.05.008_bb0240","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0166-6851(01)00432-7","article-title":"Targeted gene deletion in Leishmania major identifies leishmanolysin (GP63) as a virulence factor","volume":"120","author":"Joshi","year":"2002","journal-title":"Mol Biochem Parasitol"},{"key":"10.1016\/j.intimp.2011.05.008_bb0245","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.4049\/jimmunol.179.5.3161","article-title":"SIR2-deficient Leishmania infantum induces a defined IFN-\u03b3\/IL-10 pattern that correlates with protection","volume":"179","author":"Silvestre","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.intimp.2011.05.008_bb0250","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1128\/IAI.70.1.62-68.2002","article-title":"Reduced infectivity of a Leishmania donovani biopterin transporter genetic mutant and its use as an attenuated strain for vaccination","volume":"70","author":"Papadopoulou","year":"2002","journal-title":"Infect Immun"},{"key":"10.1016\/j.intimp.2011.05.008_bb0255","doi-asserted-by":"crossref","first-page":"25703","DOI":"10.1074\/jbc.M402794200","article-title":"Centrin gene disruption impairs stage-specific basal body duplication and cell cycle progression in Leishmania","volume":"279","author":"Selvapandiyan","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.intimp.2011.05.008_bb0260","first-page":"455","article-title":"Genetically modified live attenuated parasites as vaccines for leishmaniasis","volume":"123","author":"Selvapandiyan","year":"2006","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.intimp.2011.05.008_bb0265","doi-asserted-by":"crossref","first-page":"6372","DOI":"10.1128\/IAI.73.10.6372-6382.2005","article-title":"Live nonpathogenic parasitic vector as a candidate vaccine against visceral leishmaniasis","volume":"73","author":"Breton","year":"2005","journal-title":"Infect Immun"},{"key":"10.1016\/j.intimp.2011.05.008_bb0270","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/ni1162","article-title":"Inflammatory mediators are insufficient for full dendritic cell activation and promote expansion of CD4+ T cell populations lacking helper function","volume":"6","author":"Sporri","year":"2005","journal-title":"Nat Immunol"},{"key":"10.1016\/j.intimp.2011.05.008_bb0275","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.0105-2896.2006.00400.x","article-title":"Th1 memory: implications for vaccine development","volume":"211","author":"Foulds","year":"2006","journal-title":"Immunol Rev"},{"key":"10.1016\/j.intimp.2011.05.008_bb0280","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00005-008-0010-9","article-title":"Live attenuated Leishmania vaccines: a potential strategic alternative","volume":"56","author":"Silvestre","year":"2008","journal-title":"Arch Immunol Ther Exp"},{"issue":"1","key":"10.1016\/j.intimp.2011.05.008_bb0285","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1086\/513821","article-title":"Protection against Leishmania major challenge infection in mice vaccinated with live recombinant parasites expressing a cytotoxic gene","volume":"177","author":"Muyombwe","year":"1998","journal-title":"J Infect Dis"},{"key":"10.1016\/j.intimp.2011.05.008_bb0290","first-page":"13","article-title":"Introduction of three independent selection markers in Leishmania","volume":"7","author":"Davoudi","year":"2003","journal-title":"Iran Biomed J"},{"key":"10.1016\/j.intimp.2011.05.008_bb0295","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.vaccine.2004.08.032","article-title":"Development of a recombinant Leishmania major strain sensitive to ganciclovir and 5-fluorocytosine for use as a live vaccine challenge in clinical trials","volume":"23","author":"Davoudi","year":"2005","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.intimp.2011.05.008_bb0300","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/eji.200838389","article-title":"Photodynamic vaccination of hamsters with inducible suicidal mutants of Leishmania amazonensis elicits immunity against visceral leishmaniasis","volume":"39","author":"Kumari","year":"2009","journal-title":"Eur J Immunol"},{"issue":"4","key":"10.1016\/j.intimp.2011.05.008_bb0305","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/0035-9203(79)90159-7","article-title":"A field trial of a vaccine against American dermal leishmaniasis","volume":"73","author":"Mayrink","year":"1979","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"3","key":"10.1016\/j.intimp.2011.05.008_bb0310","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/00034983.1985.11811917","article-title":"An experimental vaccine against American dermal leishmaniasis: experience in the State of Espirito Santo, Brazil","volume":"79","author":"Mayrink","year":"1985","journal-title":"Ann Trop Med Parasitol"},{"issue":"6","key":"10.1016\/j.intimp.2011.05.008_bb0315","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/S0035-9203(00)90239-6","article-title":"Safety and immunogenicity of a killed Leishmania (L.) amazonensis vaccine against cutaneous leishmaniasis in Colombia: a randomized controlled trial","volume":"94","author":"Velez","year":"2000","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"8","key":"10.1016\/j.intimp.2011.05.008_bb0320","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.trstmh.2005.04.002","article-title":"Failure of a killed Leishmania amazonensis vaccine against American cutaneous leishmaniasis in Colombia","volume":"99","author":"Velez","year":"2005","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.intimp.2011.05.008_bb0325","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.vaccine.2003.06.002","article-title":"Safety, immunogenicity, and efficacy of an autoclaved Leishmania amazonensis vaccine plus BCG adjuvant against New World cutaneous leishmaniasis","volume":"22","author":"Armijos","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2011.05.008_bb0330","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/0264-410X(94)90149-X","article-title":"Immune response in healthy volunteers vaccinated with BCG plus killed leishmanial promastigotes: antibody responses to mycobacterial and leishmanial antigens","volume":"12","author":"Sharples","year":"1994","journal-title":"Vaccine"},{"issue":"8530","key":"10.1016\/j.intimp.2011.05.008_bb0335","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0140-6736(87)90116-4","article-title":"Immunotherapy versus chemotherapy in localised cutaneous leishmaniasis","volume":"1","author":"Convit","year":"1987","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2011.05.008_bb0340","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0035-9203(03)90093-9","article-title":"Immunotherapy of American cutaneous leishmaniasis in Venezuela during the period 1990\u201399","volume":"97","author":"Convit","year":"2003","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.intimp.2011.05.008_bb0345","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1046\/j.1365-3024.2000.00278.x","article-title":"Immunotherapy with live BCG plus heat killed Leishmania induces a T helper 1-like response in American cutaneous leishmaniasis patients","volume":"22","author":"Cabrera","year":"2000","journal-title":"Parasite Immunol"},{"key":"10.1016\/j.intimp.2011.05.008_bb0350","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1046\/j.1365-4362.2002.01336.x","article-title":"Immunochemotherapy for cutaneous leishmaniasis: a controlled trial using killed Leishmania amazonensis vaccine plus antimonial","volume":"41","author":"Machado-Pinto","year":"2002","journal-title":"Int J Dermatol"},{"issue":"5","key":"10.1016\/j.intimp.2011.05.008_bb0355","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1086\/515265","article-title":"Field trial of a vaccine against New World cutaneous leishmaniasis in an at-risk child population: safety, immunogenicity, and efficacy during the first 12 months of follow-up","volume":"177","author":"Armijos","year":"1998","journal-title":"J Infect Dis"},{"issue":"12","key":"10.1016\/j.intimp.2011.05.008_bb0360","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1086\/375399","article-title":"Field trial of a vaccine against new world cutaneous leishmaniasis in an at-risk child population: how long does protection last?","volume":"187","author":"Armijos","year":"2003","journal-title":"J Infect Dis"},{"issue":"52","key":"10.1016\/j.intimp.2011.05.008_bb0365","doi-asserted-by":"crossref","first-page":"6759","DOI":"10.1016\/j.vaccine.2008.09.085","article-title":"First generation leishmaniasis vaccines: a review of field efficacy trials","volume":"26","author":"Noazin","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2011.05.008_bb0370","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1590\/S0074-02762004000100010","article-title":"Therapy of Venezuelan patients with severe mucocutaneous or early lesions of diffuse cutaneous leishmaniasis with a vaccine containing pasteurized Leishmania promastigotes and Bacillus Calmette-Guerin: preliminary report","volume":"99","author":"Convit","year":"2004","journal-title":"Mem Inst Oswaldo Cruz"},{"issue":"6","key":"10.1016\/j.intimp.2011.05.008_bb0375","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1590\/S0074-02761996000600006","article-title":"Phase I and II open clinical trials of a vaccine against Leishmania chagasi infections in dogs","volume":"91","author":"Mayrink","year":"1996","journal-title":"Mem Inst Oswaldo Cruz"},{"issue":"44","key":"10.1016\/j.intimp.2011.05.008_bb0380","doi-asserted-by":"crossref","first-page":"7674","DOI":"10.1016\/j.vaccine.2007.08.009","article-title":"Immunogenicity of a killed Leishmania vaccine with saponin adjuvant in dogs","volume":"25","author":"Giunchetti","year":"2007","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.intimp.2011.05.008_bb0385","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.rvsc.2007.09.008","article-title":"Antigenicity of a whole parasite vaccine as promising candidate against canine leishmaniasis","volume":"85","author":"Giunchetti","year":"2008","journal-title":"Res Vet Sci"},{"issue":"6","key":"10.1016\/j.intimp.2011.05.008_bb0390","doi-asserted-by":"crossref","first-page":"826","DOI":"10.4269\/ajtmh.1994.51.826","article-title":"Endemic kala-azar in Eastern Sudan: a longitudinal study on the incidence of clinical and subclinical infection and post kala-azar dermal leishmaniasis","volume":"51","author":"Zijlstra","year":"1994","journal-title":"Am J Trop Med Hyg"},{"issue":"25\u201326","key":"10.1016\/j.intimp.2011.05.008_bb0395","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1016\/S0264-410X(01)00058-5","article-title":"Successful vaccination against Leishmania donovani infection in Indian langur using alum-precipitated autoclaved Leishmania major with BCG","volume":"19","author":"Misra","year":"2001","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.intimp.2011.05.008_bb0400","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1084\/jem.20020147","article-title":"Vaccination with heat-killed Leishmania antigen or recombinant leishmanial protein and CpG oligodeoxynucleotides induces long-term memory CD4+ and CD8+ T cell responses and protection against Leishmania major infection","volume":"195","author":"Rhee","year":"2002","journal-title":"J Exp Med"},{"issue":"2","key":"10.1016\/j.intimp.2011.05.008_bb0405","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1017\/S0031182003003457","article-title":"Prophylactic potential of autoclaved Leishmania donovani with BCG against experimental visceral leishmaniasis","volume":"127","author":"Srivastava","year":"2003","journal-title":"Parasitology"},{"issue":"1","key":"10.1016\/j.intimp.2011.05.008_bb0410","first-page":"159","article-title":"The adjuvant effects of IL-12 and BCG on autoclaved Leishmania major vaccine in experimental cutaneous leishmaniasis","volume":"36","author":"Michel","year":"2006","journal-title":"J Egypt Soc Parasitol"},{"issue":"4","key":"10.1016\/j.intimp.2011.05.008_bb0415","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.parint.2009.07.008","article-title":"Induction of cellular and humoral responses by autoclaved and heat-killed antigen of Leishmania donovani in experimental visceral leishmaniasis","volume":"58","author":"Nagill","year":"2009","journal-title":"Parasitol Int"},{"key":"10.1016\/j.intimp.2011.05.008_bb0420","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/S0264-410X(98)00220-5","article-title":"A randomised, double blind, controlled trial of a killed L. major vaccine plus BCG against zoonotic cutaneous leishmaniasis in Iran","volume":"17","author":"Momeni","year":"1998","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2011.05.008_bb0425","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(98)09552-X","article-title":"Randomized vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran","volume":"351","author":"Sharifi","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2011.05.008_bb0430","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/S0140-6736(00)03128-7","article-title":"Autoclaved L major vaccine for prevention of visceral leishmaniasis: a randomised double-blind BCG-controlled trial in Sudan","volume":"356","author":"Khalil","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2011.05.008_bb0435","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/S0264-410X(00)00401-1","article-title":"Immunogenicity and safety of autoclaved Leishmania major plus BCG vaccine in healthy Sudanese volunteers","volume":"19","author":"Satti","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2011.05.008_bb0440","doi-asserted-by":"crossref","first-page":"4481","DOI":"10.4049\/jimmunol.163.8.4481","article-title":"Protective immunity using recombinant human IL-12 and alum as adjuvants in a primate model of cutaneous leishmaniasis","volume":"163","author":"Kenney","year":"1999","journal-title":"J Immunol"},{"key":"10.1016\/j.intimp.2011.05.008_bb0445","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1016\/j.vaccine.2004.03.058","article-title":"Double-blind randomized efficacy field trial of alum precipitated autoclaved Leishmania major vaccine mixed with BCG against canine visceral leishmaniasis in Meshkin-Shahr district, I.R. Iran","volume":"22","author":"Mohebali","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2011.05.008_bb0450","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0035-9203(03)90171-4","article-title":"Alum precipitated autoclaved L major plus BCG a candidate vaccine for visceral leishmaniasis: safety skin delayed hypersensitivity response and dose finding in healthy volunteers","volume":"97","author":"Kamil","year":"2003","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"4","key":"10.1016\/j.intimp.2011.05.008_bb0455","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1179\/146532806X152890","article-title":"Safety and immunogenicity of a candidate vaccine for visceral leishmaniasis (Alum-precipitated autoclaved Leishmania major + BCG) in children: an extended phase II study","volume":"26","author":"Khalil","year":"2006","journal-title":"Ann Trop Paediatr"},{"key":"10.1016\/j.intimp.2011.05.008_bb0460","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1475-9292-6-7","article-title":"Consultation meeting on the development of therapeutic vaccines for post kala azar dermal leishmaniasis","volume":"6","author":"Ghalib","year":"2007","journal-title":"Kinetoplastid Biol Dis"},{"key":"10.1016\/j.intimp.2011.05.008_bb0465","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.4049\/jimmunol.145.7.2281","article-title":"Oral Salmonella typhimurium (AroA\u2212) vaccine expressing a major leishmanial surface protein (gp63) preferentially induces T helper 1 cells and protective immunity against leishmaniasis","volume":"145","author":"Yang","year":"1990","journal-title":"J Immunol"},{"key":"10.1016\/j.intimp.2011.05.008_bb0470","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1084\/jem.181.4.1527","article-title":"A recombinant Leishmania antigen that stimulates human peripheral blood mononuclear cells to express a Th1-type cytokine profile and to produce interleukin 12","volume":"181","author":"Skeiky","year":"1995","journal-title":"J Exp Med"},{"key":"10.1016\/j.intimp.2011.05.008_bb0475","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1084\/jem.186.7.1137","article-title":"Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major","volume":"186","author":"Gurunathan","year":"1997","journal-title":"J Exp Med"},{"key":"10.1016\/j.intimp.2011.05.008_bb0480","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1128\/IAI.57.3.754-763.1989","article-title":"Inhibition of Leishmania donovani promastigote internalization into murine macrophages by chemically defined parasite glycoconjugate","volume":"57","author":"Palatnik de Sousa","year":"1989","journal-title":"Infect Immun"},{"key":"10.1016\/j.intimp.2011.05.008_bb0485","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.4049\/jimmunol.147.10.3538","article-title":"The Leishmania donovani lipophosphoglycan T lymphocyte reactive component is a tightly associated protein complex","volume":"147","author":"Jardim","year":"1991","journal-title":"J Immunol"},{"key":"10.1016\/j.intimp.2011.05.008_bb0490","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.4049\/jimmunol.150.6.2322","article-title":"Pure protein from Leishmania donovani protects mice against both cutaneous and visceral leishmaniasis","volume":"150","author":"Rachamim","year":"1993","journal-title":"J Immunol"},{"key":"10.1016\/j.intimp.2011.05.008_bb0495","doi-asserted-by":"crossref","first-page":"3608","DOI":"10.4049\/jimmunol.137.11.3608","article-title":"Passive transfer of Leishmania lipopolysaccharide confers parasite survival in macrophages","volume":"137","author":"Handman","year":"1986","journal-title":"J Immunol"},{"key":"10.1016\/j.intimp.2011.05.008_bb0500","doi-asserted-by":"crossref","first-page":"5595","DOI":"10.1128\/IAI.68.10.5595-5602.2000","article-title":"Identification of vaccine candidates for experimental visceral leishmaniasis by immunization with sequential fractions of a cDNA expression library","volume":"68","author":"Melby","year":"2000","journal-title":"Infect Immun"},{"key":"10.1016\/j.intimp.2011.05.008_bb0505","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.4049\/jimmunol.138.5.1596","article-title":"Identification of specific and cross-reactive antigens of Leishmania donovani chagasi by human infection sera","volume":"138","author":"Reed","year":"1987","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.intimp.2011.05.008_bb0510","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1073\/pnas.90.2.775","article-title":"Molecular characterization of a kinesin related antigen of Leishmania chagasi that detects specific antibody in African and American visceral leishmaniasis","volume":"90","author":"Burns","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.intimp.2011.05.008_bb0515","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1128\/IAI.63.10.4105-4114.1995","article-title":"Immune responses of leishmaniasis patients to heat shock proteins of Leishmania species and humans","volume":"63","author":"Skeiky","year":"1995","journal-title":"Infect Immun"},{"key":"10.1016\/j.intimp.2011.05.008_bb0520","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0166-6851(97)00115-1","article-title":"Molecular characterization of the heat inducible LmSTI1 protein of Leishmania major","volume":"89","author":"Webb","year":"1997","journal-title":"Mol Biochem Parasitol"},{"issue":"11","key":"10.1016\/j.intimp.2011.05.008_bb0525","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.4049\/jimmunol.157.11.5034","article-title":"Molecular cloning of a novel protein antigen of Leishmania major that elicits a potent immune response in experimental murine leishmaniasis","volume":"157","author":"Webb","year":"1996","journal-title":"J Immunol"},{"issue":"11","key":"10.1016\/j.intimp.2011.05.008_bb0530","doi-asserted-by":"crossref","first-page":"6171","DOI":"10.4049\/jimmunol.161.11.6171","article-title":"LeIF: a recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile","volume":"161","author":"Skeiky","year":"1998","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.intimp.2011.05.008_bb0535","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0166-6851(00)00377-7","article-title":"Identification of Leishmania major cysteine proteinases as targets of the immune response in humans","volume":"113","author":"Rafati","year":"2001","journal-title":"Mol Biochem Parasitol"},{"key":"10.1016\/j.intimp.2011.05.008_bb0540","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1046\/j.1365-3024.1999.00244.x","article-title":"Vaccination against Leishmania major in a CBA mouse model of infection: role of adjuvants and mechanism of protection","volume":"21","author":"Rivier","year":"1999","journal-title":"Parasite Immunol"},{"issue":"4","key":"10.1016\/j.intimp.2011.05.008_bb0545","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/0014-4894(90)90127-X","article-title":"Leishmania major: production of recombinant gp63 its antigenicity and immunogenicity in mice","volume":"70","author":"Handman","year":"1990","journal-title":"Exp Parasitol"},{"issue":"3\u20134","key":"10.1016\/j.intimp.2011.05.008_bb0550","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0304-4017(95)00788-6","article-title":"Vaccination of vervet monkeys against cutaneous leishmaniosis using recombinant Leishmania major \u2018surface glycoprotein\u2019 (gp63)","volume":"60","author":"Olobo","year":"1995","journal-title":"Vet Parasitol"},{"issue":"4","key":"10.1016\/j.intimp.2011.05.008_bb0555","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.4049\/jimmunol.140.4.1274","article-title":"Effective immunization cutaneous leishmaniasis with defined membrane antigens reconstituted into liposomes","volume":"140","author":"Russell","year":"1988","journal-title":"J Immunol"},{"key":"10.1016\/j.intimp.2011.05.008_bb0560","first-page":"1","article-title":"Protection against Leishmania major infection in genetically susceptible BALB\/c mice by gp63 delivered orally in attenuated Salmonella typhimurium (AroA\u2212 AroD\u2212)","volume":"85","author":"Xu","year":"1995","journal-title":"Immunology"},{"key":"10.1016\/j.intimp.2011.05.008_bb0565","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1128\/IAI.65.1.171-178.1997","article-title":"Vaccine efficacy of Salmonella strains expressing glycoprotein 63 with different promoters","volume":"65","author":"McSorley","year":"1997","journal-title":"Infect Immun"},{"key":"10.1016\/j.intimp.2011.05.008_bb0570","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/S0264-410X(97)00267-3","article-title":"Immunogenicity of a Salmonella typhi CVD 908 candidate vaccine strain expressing the major surface protein gp63 of Leishmania mexicana mexicana","volume":"16","author":"Gonzalez","year":"1998","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2011.05.008_bb0575","doi-asserted-by":"crossref","first-page":"11473","DOI":"10.1073\/pnas.90.24.11473","article-title":"Effective immunization against cutaneous leishmaniasis with recombinant bacille Calmette-Guerin expressing the Leishmania surface proteinase gp63","volume":"15","author":"Connell","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.intimp.2011.05.008_bb0580","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1099\/13500872-141-7-1585","article-title":"Recombinant BCG expressing the Leishmania surface antigen Gp63 induces protective immunity against Leishmania major infection in BALB\/c mice","volume":"141","author":"Abdelhak","year":"1995","journal-title":"Microbiology"},{"issue":"29\u201330","key":"10.1016\/j.intimp.2011.05.008_bb0585","doi-asserted-by":"crossref","first-page":"5708","DOI":"10.1016\/j.vaccine.2006.04.062","article-title":"Immune response and protection assay of recombinant major surface glycoprotein of Leishmania (rgp63) reconstituted with liposomes in BALB\/c mice","volume":"24","author":"Jaafari","year":"2006","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.intimp.2011.05.008_bb0590","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1128\/IAI.00611-07","article-title":"gp63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB\/c mice infected with Leishmania donovani","volume":"76","author":"Bhowmick","year":"2008","journal-title":"Infect Immun"},{"issue":"2","key":"10.1016\/j.intimp.2011.05.008_bb0595","doi-asserted-by":"crossref","first-page":"699","DOI":"10.4049\/jimmunol.144.2.699","article-title":"Characterization of two proteins from Leishmania donovani and their use for vaccination against visceral leishmaniasis","volume":"144","author":"Jaffe","year":"1990","journal-title":"J Immunol"},{"key":"10.1016\/j.intimp.2011.05.008_bb0600","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1365-3083.1991.tb03752.x","article-title":"Activation of human T lymphocytes by Leishmania lipophosphoglycan","volume":"33","author":"Kemp","year":"1991","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.intimp.2011.05.008_bb0605","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/j.1365-2249.1991.tb05663.x","article-title":"Analysis of the human T cell responsiveness to purified antigens of Leishmania: lipophosphoglycan (LPG) and glycoprotein 63 (gp 63)","volume":"83","author":"Mendonca","year":"1991","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.intimp.2011.05.008_bb0610","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.4049\/jimmunol.147.10.3575","article-title":"Human T-cell responses to gp63 a surface antigen of Leishmania","volume":"147","author":"Russo","year":"1991","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.intimp.2011.05.008_bb0615","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1084\/jem.172.2.645","article-title":"Immunoprotective Leishmania major synthetic T cell epitopes","volume":"172","author":"Jardim","year":"1990","journal-title":"J Exp Med"},{"key":"10.1016\/j.intimp.2011.05.008_bb0620","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/S0264-410X(98)00363-6","article-title":"Long-term protection of mice against Leishmania major with a synthetic peptide vaccine","volume":"17","author":"Spitzer","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2011.05.008_bb0625","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.4049\/jimmunol.170.6.3171","article-title":"Dendritic cell (DC)-based protection against an intracellular pathogen is dependent upon DC-derived IL-12 and can be induced by molecularly defined antigens","volume":"170","author":"Berberich","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.intimp.2011.05.008_bb0630","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1177\/039463200401700314","article-title":"Dendritic cells pulsed with peptides of gp63 induce differential protection against experimental cutaneous leishmaniasis","volume":"17","author":"Tsagozis","year":"2004","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1016\/j.intimp.2011.05.008_bb0635","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1128\/IAI.69.5.3255-3263.2001","article-title":"Vaccination against the intracellular pathogens Leishmania major and L amazonensis by directing CD40 ligand to macrophages","volume":"69","author":"Chen","year":"2001","journal-title":"Infect Immun"},{"issue":"21","key":"10.1016\/j.intimp.2011.05.008_bb0640","doi-asserted-by":"crossref","first-page":"8393","DOI":"10.1073\/pnas.87.21.8393","article-title":"Molecular cloning and characterization of the immunologically protective surface glycoprotein GP46\/M-2 of Leishmania amazonensis","volume":"87","author":"Lohman","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.intimp.2011.05.008_bb0645","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.4049\/jimmunol.138.5.1587","article-title":"Structural and antigenic characterization of a species- and promastigote-specific Leishmania mexicana amazonensis membrane protein","volume":"138","author":"Kahl","year":"1987","journal-title":"J Immunol"},{"key":"10.1016\/j.intimp.2011.05.008_bb0650","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0166-6851(92)90252-F","article-title":"Loss of the GP46\/M2 surface membrane glycoprotein gene family in the Leishmania braziliensis complex","volume":"50","author":"McMahon-Pratt","year":"1992","journal-title":"Mol Biochem Parasitol"},{"key":"10.1016\/j.intimp.2011.05.008_bb0655","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0166-6851(94)90100-7","article-title":"Characterization of a polymorphic family of integral membrane proteins in promastigotes of different Leishmania species","volume":"67","author":"Symons","year":"1994","journal-title":"Mol Biochem Parasitol"},{"key":"10.1016\/j.intimp.2011.05.008_bb0660","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1128\/IAI.56.12.3272-3279.1988","article-title":"Membrane glycoprotein M-2 protects against Leishmania amazonensis infection","volume":"56","author":"Champsi","year":"1988","journal-title":"Infect Immun"},{"issue":"8","key":"10.1016\/j.intimp.2011.05.008_bb0665","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1128\/IAI.61.8.3351-3359.1993","article-title":"Recombinant vaccinia viruses expressing GP46\/M-2 protect against Leishmania infection","volume":"61","author":"McMahon-Pratt","year":"1993","journal-title":"Infect Immun"},{"issue":"10","key":"10.1016\/j.intimp.2011.05.008_bb0670","doi-asserted-by":"crossref","first-page":"5654","DOI":"10.1128\/IAI.72.10.5654-5661.2004","article-title":"Immunization with Leishmania major exogenous antigens protects susceptible BALB\/c mice against challenge infection with L major","volume":"72","author":"Tonui","year":"2004","journal-title":"Infect Immun"},{"key":"10.1016\/j.intimp.2011.05.008_bb0675","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.4049\/jimmunol.172.8.4902","article-title":"A leucine-rich repeat motif of Leishmania parasite surface antigen 2 binds to macrophages through the complement receptor 3","volume":"172","author":"Kedzierski","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.intimp.2011.05.008_bb0680","doi-asserted-by":"crossref","first-page":"24477","DOI":"10.1016\/S0021-9258(18)54253-8","article-title":"Variants of a Leishmania surface antigen derived from a multigenic family","volume":"266","author":"Murray","year":"1991","journal-title":"J Biol Chem"},{"issue":"11","key":"10.1016\/j.intimp.2011.05.008_bb0685","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1128\/IAI.63.11.4261-4267.1995","article-title":"Protective vaccination with promastigote surface antigen 2 from Leishmania major is mediated by a TH1 type of immune response","volume":"63","author":"Handman","year":"1995","journal-title":"Infect Immun"},{"issue":"20","key":"10.1016\/j.intimp.2011.05.008_bb0690","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/S0264-410X(98)00075-9","article-title":"Vaccination with recombinant Parasite Surface Antigen 2 from Leishmania major induces a Th1 type of immune response but does not protect against infection","volume":"16","author":"Sjolander","year":"1998","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.intimp.2011.05.008_bb0695","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1574-695X.1998.tb01129.x","article-title":"The Leishmania promastigote surface antigen-2 (PSA-2) is specifically recognised by Th1 cells in humans with naturally acquired immunity to L. major","volume":"20","author":"Kemp","year":"1998","journal-title":"FEMS Immunol Med Microbiol"},{"key":"10.1016\/j.intimp.2011.05.008_bb0700","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1126\/science.7725103","article-title":"Expression cloning of a protective Leishmania antigen","volume":"268","author":"Mougneau","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.intimp.2011.05.008_bb0705","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1046\/j.1432-1327.1999.00122.x","article-title":"Molecular cloning cell localization and binding affinity to DNA replication proteins of the p36\/LACK protective antigen from Leishmania infantum","volume":"259","author":"Gonzalez-Aseguinolaza","year":"1999","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.intimp.2011.05.008_bb0710","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1126\/science.274.5286.421","article-title":"Resistance to Leishmania major induced by tolerance to a single antigen","volume":"274","author":"Julia","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.intimp.2011.05.008_bb0715","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S1074-7613(00)80342-8","article-title":"IL-4 rapidly produced by V beta 4 V alpha 8 CD4+ T cells instructs Th2 development and susceptibility to Leishmania major in BALB\/c mice","volume":"6","author":"Launois","year":"1997","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2011.05.008_bb0720","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/4000","article-title":"Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection","volume":"4","author":"Gurunathan","year":"1998","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.intimp.2011.05.008_bb0725","doi-asserted-by":"crossref","first-page":"3988","DOI":"10.1128\/IAI.71.7.3988-3994.2003","article-title":"Immune responses induced by the Leishmania (Leishmania) donovani A2 antigen but not by the LACK antigen are protective against experimental Leishmania (Leishmania) amazonensis infection","volume":"71","author":"Ferraz Coelho","year":"2003","journal-title":"Infect Immun"},{"key":"10.1016\/j.intimp.2011.05.008_bb0730","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1128\/IAI.72.8.4521-4527.2004","article-title":"Intranasal vaccination against cutaneous leishmaniasis with a particulated leishmanial antigen or DNA encoding LACK","volume":"72","author":"Pinto","year":"2004","journal-title":"Infect Immun"},{"issue":"6","key":"10.1016\/j.intimp.2011.05.008_bb0735","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1128\/IAI.70.6.3122-3129.2002","article-title":"LACK-specific CD4+ T cells that induce gamma interferon production in patients with localized cutaneous leishmaniasis during an early stage of infection","volume":"70","author":"Bourreau","year":"2002","journal-title":"Infect Immun"},{"issue":"2","key":"10.1016\/j.intimp.2011.05.008_bb0740","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1086\/315725","article-title":"A Leishmania homologue of receptors for activated C-kinase (LACK) induces both interferon-\u03b3 and interleukin-10 in natural killer cells of healthy blood donors","volume":"182","author":"Maasho","year":"2000","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.intimp.2011.05.008_bb0745","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/1521-4141(200202)32:2<510::AID-IMMU510>3.0.CO;2-4","article-title":"IFN-\u03b3-producing CD45RA+ CD8+ and IL-10-producing CD45RA\u2212 CD4+ T cells generated in response to LACK in naive subjects never exposed to Leishmania","volume":"32","author":"Bourreau","year":"2002","journal-title":"Eur J Immunol"},{"issue":"4","key":"10.1016\/j.intimp.2011.05.008_bb0750","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1365-3083.2005.01581.x","article-title":"Effect of LACK and KMP11 on IFN-\u03b3 production by peripheral blood mononuclear cells from cutaneous and mucosal leishmaniasis patients","volume":"61","author":"Carvalho","year":"2005","journal-title":"Scand J Immunol"},{"issue":"12","key":"10.1016\/j.intimp.2011.05.008_bb0755","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1016\/j.vaccine.2006.11.057","article-title":"Palatnik de Sousa CB, Menz I. Safety trial using the Leishmune\u00ae vaccine against canine visceral leishmaniasis in Brazil","volume":"25","author":"Parra","year":"2007","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.intimp.2011.05.008_bb0760","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/0001-706X(93)90006-W","article-title":"Leishmania donovani surface glycoconjugate GP36 is the major immunogen component of the fucose-mannose ligand (FML)","volume":"53","author":"Palatnik de Sousa","year":"1993","journal-title":"Acta Trop"},{"issue":"2","key":"10.1016\/j.intimp.2011.05.008_bb0765","first-page":"547","article-title":"Experimental murine Leishmania donovani infection: immunoprotection by the fucose-mannose ligand (FML)","volume":"27","author":"Palatnik de Sousa","year":"1994","journal-title":"Braz J Med Biol Res"},{"issue":"32","key":"10.1016\/j.intimp.2011.05.008_bb0770","doi-asserted-by":"crossref","first-page":"4668","DOI":"10.1016\/S0264-410X(03)00527-9","article-title":"Immunotherapy against murine experimental visceral leishmaniasis with the FML-vaccine","volume":"21","author":"Santos","year":"2003","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.intimp.2011.05.008_bb0775","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1590\/S0037-86821996000200008","article-title":"The FML (Fucose Mannose Ligand) of Leishmania donovani. A new tool in diagnosis prognosis transfusional control and vaccination against human kala-azar","volume":"29","author":"Palatnik de Sousa","year":"1996","journal-title":"Rev Soc Bras Med Trop"},{"key":"10.1016\/j.intimp.2011.05.008_bb0780","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1016\/S0264-410X(99)00058-4","article-title":"Vaccination of Swiss Albino mice against experimental visceral leishmaniasis with the FML antigen of Leishmania donovani","volume":"17","author":"Santos","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2011.05.008_bb0785","first-page":"290","article-title":"The FML vaccine (fucose-mannose ligand) protects hamsters from experimental kala-azar Ciencia e Cultura","volume":"46","author":"Palatnik de Sousa","year":"1994","journal-title":"J Braz Assoc Adv Sci"},{"issue":"1\u20132","key":"10.1016\/j.intimp.2011.05.008_bb0790","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0264-410X(02)00444-9","article-title":"Saponins, IL12 and BCG adjuvant in the FML-vaccine formulation against murine visceral leishmaniasis","volume":"21","author":"Santos","year":"2002","journal-title":"Vaccine"},{"issue":"18","key":"10.1016\/j.intimp.2011.05.008_bb0795","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1016\/j.vaccine.2006.02.034","article-title":"Acylated and deacylated saponins of Quillaja saponaria mixture as adjuvants for the FML-vaccine against visceral leishmaniasis","volume":"24","author":"Oliveira-Freitas","year":"2006","journal-title":"Vaccine"},{"issue":"23\u201324","key":"10.1016\/j.intimp.2011.05.008_bb0800","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1016\/S0264-410X(01)00031-7","article-title":"Vaccination of Balb\/c mice against experimental visceral leishmaniasis with the GP36 glycoprotein antigen of Leishmania donovani","volume":"19","author":"Paraguai de Souza","year":"2001","journal-title":"Vaccine"},{"issue":"9\u201310","key":"10.1016\/j.intimp.2011.05.008_bb0805","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/S0264-410X(00)00339-X","article-title":"A phase III trial of efficacy of the FML-vaccine against canine kala-azar in an endemic area of Brazil (S\u00e3o Gon\u00e7alo do Amaranto RN)","volume":"19","author":"da Silva","year":"2000","journal-title":"Vaccine"},{"issue":"27\u201328","key":"10.1016\/j.intimp.2011.05.008_bb0810","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1016\/S0264-410X(02)00294-3","article-title":"Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (Sao Goncalo do Amarante RN)","volume":"20","author":"Borja-Cabrera","year":"2002","journal-title":"Vaccine"},{"issue":"17\u201318","key":"10.1016\/j.intimp.2011.05.008_bb0815","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1016\/j.vaccine.2003.11.039","article-title":"Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine","volume":"22","author":"Borja-Cabrera","year":"2004","journal-title":"Vaccine"},{"issue":"33","key":"10.1016\/j.intimp.2011.05.008_bb0820","doi-asserted-by":"crossref","first-page":"6176","DOI":"10.1016\/j.vaccine.2007.06.005","article-title":"Immunotherapy against experimental canine visceral leishmaniasis with the saponin enriched-Leishmune\u00ae vaccine","volume":"25","author":"Santos","year":"2007","journal-title":"Vaccine"},{"issue":"39","key":"10.1016\/j.intimp.2011.05.008_bb0825","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1016\/j.vaccine.2008.07.029","article-title":"Immunogenicity assay of the Leishmune\u00ae vaccine against canine visceral leishmaniasis in Brazil","volume":"26","author":"Borja-Cabrera","year":"2008","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.intimp.2011.05.008_bb0830","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1586\/14760584.7.6.833","article-title":"FML vaccine against canine visceral leishmaniasis: from second-generation to synthetic vaccine","volume":"7","author":"Palatnik de Sousa","year":"2008","journal-title":"Expert Rev Vaccines"},{"issue":"18","key":"10.1016\/j.intimp.2011.05.008_bb0835","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1016\/j.vaccine.2008.02.044","article-title":"Despite Leishvaccine and Leishmune\u00ae trigger distinct immune profiles their ability to activate phagocytes and CD8+ T-cells support their high-quality immunogenic potential against canine visceral leishmaniasis","volume":"26","author":"Araujo","year":"2008","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.intimp.2011.05.008_bb0840","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.vaccine.2008.11.104","article-title":"T-cell-derived cytokines nitric oxide production by peripheral blood monocytes and seric anti-Leishmania (Leishmania) chagasi IgG subclass patterns following immunization against canine visceral leishmaniasis using Leishvaccine and Leishmune","volume":"27","author":"Araujo","year":"2009","journal-title":"Vaccine"},{"issue":"40","key":"10.1016\/j.intimp.2011.05.008_bb0845","doi-asserted-by":"crossref","first-page":"4805","DOI":"10.1016\/j.vaccine.2005.05.011","article-title":"Leishmune\u00ae vaccine blocks the transmission of canine visceral leishmaniasis: absence of Leishmania parasites in blood skin and lymph nodes of vaccinated exposed dogs","volume":"23","author":"Nogueira","year":"2005","journal-title":"Vaccine"},{"issue":"13","key":"10.1016\/j.intimp.2011.05.008_bb0850","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1016\/j.vaccine.2005.11.061","article-title":"The FML-vaccine (Leishmune\u00ae) against canine visceral leishmaniasis: a transmission blocking vaccine","volume":"24","author":"Saraiva","year":"2006","journal-title":"Vaccine"},{"issue":"1\u20132","key":"10.1016\/j.intimp.2011.05.008_bb0855","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vetpar.2006.05.001","article-title":"Leishmune\u00ae vaccine: the newest tool for prevention and control of canine visceral leishmaniosis and its potential as a transmission-blocking vaccine","volume":"141","author":"Dantas-Torres","year":"2006","journal-title":"Vet Parasitol"},{"issue":"2","key":"10.1016\/j.intimp.2011.05.008_bb0860","doi-asserted-by":"crossref","first-page":"296","DOI":"10.4269\/ajtmh.1999.61.296","article-title":"The fucose-mannose ligand-ELISA in the diagnosis and prognosis of canine visceral leishmaniasis in Brazil","volume":"61","author":"Borja-Cabrera","year":"1999","journal-title":"Am J Trop Med Hyg"},{"issue":"4","key":"10.1016\/j.intimp.2011.05.008_bb0865","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/0035-9203(95)90022-5","article-title":"Leishmania donovani: titration of antibodies to the fucose-mannose ligand as an aid in diagnosis and prognosis of visceral leishmaniasis","volume":"89","author":"Palatnik de Sousa","year":"1995","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.intimp.2011.05.008_bb0870","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1016\/j.vaccine.2004.11.061","article-title":"Protection against experimental visceral leishmaniasis infection in dogs immunized with purified excreted secreted antigens of Leishmania infantum promastigotes","volume":"23","author":"Lemesre","year":"2005","journal-title":"Vaccine"},{"issue":"21","key":"10.1016\/j.intimp.2011.05.008_bb0875","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1016\/j.vaccine.2007.02.083","article-title":"Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial","volume":"25","author":"Lemesre","year":"2007","journal-title":"Vaccine"},{"issue":"1\u20133","key":"10.1016\/j.intimp.2011.05.008_bb0880","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.vetimm.2008.10.309","article-title":"Effective humoral and cellular immunoprotective responses in LiESAp-MDP vaccinated protected dogs","volume":"128","author":"Bourdoiseau","year":"2009","journal-title":"Vet Immunol Immunopathol"},{"issue":"3\u20134","key":"10.1016\/j.intimp.2011.05.008_bb0885","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.vetimm.2005.03.001","article-title":"Lymphocytes of dogs immunised with purified excreted-secreted antigens of Leishmania infantum co-incubated with Leishmania infected macrophages produce IFN gamma resulting in nitric oxide-mediated amastigote apoptosis","volume":"106","author":"Holzmuller","year":"2005","journal-title":"Vet Immunol Immunopathol"},{"issue":"3","key":"10.1016\/j.intimp.2011.05.008_bb0890","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2174\/1389202033490439","article-title":"Leishmania cysteine proteinases: from gene to subunit vaccine","volume":"4","author":"Rafati","year":"2003","journal-title":"Curr Genom"},{"key":"10.1016\/j.intimp.2011.05.008_bb0895","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S0968-0896(99)00008-5","article-title":"Cysteine protease inhibitors as chemotherapy for parasitic infections","volume":"7","author":"McKerrow","year":"1999","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.intimp.2011.05.008_bb0900","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/BF02174048","article-title":"Parasite cysteine proteinases","volume":"6","author":"Robertson","year":"1996","journal-title":"Perspect Drug Discov"},{"issue":"3","key":"10.1016\/j.intimp.2011.05.008_bb0905","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1128\/IAI.68.3.1328-1336.2000","article-title":"Subunit vaccination of mice against new world cutaneous leishmaniasis: comparison of three proteins expressed in amastigotes and six adjuvants","volume":"68","author":"Aebischer","year":"2000","journal-title":"Infect Immun"},{"key":"10.1016\/j.intimp.2011.05.008_bb0910","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1046\/j.1365-2249.2000.01160.x","article-title":"Vaccination of BALB\/c mice with Leishmania major amastigote-specific cysteine proteinase","volume":"120","author":"Rafati","year":"2000","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.intimp.2011.05.008_bb0915","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1016\/S0264-410X(02)00189-5","article-title":"Recombinant cysteine proteinases-based vaccines against Leishmania major in BALB\/c mice: the partial protection relies on interferon gamma producing CD8(+) T lymphocyte activation","volume":"20","author":"Rafati","year":"2002","journal-title":"Vaccine"},{"issue":"16","key":"10.1016\/j.intimp.2011.05.008_bb0920","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1016\/j.vaccine.2003.11.014","article-title":"Immunization with the hybrid protein vaccine consisting of Leishmania major cysteine proteinases Type I (CPB) and Type II (CPA) partially protects against leishmaniasis","volume":"22","author":"Zadeh-Vakili","year":"2004","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.intimp.2011.05.008_bb0925","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1128\/IAI.71.5.2924-2926.2003","article-title":"Th1 cell development induced by cysteine proteinases A and B in localized cutaneous leishmaniasis due to Leishmania guyanensis","volume":"71","author":"Pascalis","year":"2003","journal-title":"Infect Immun"},{"issue":"3\u20134","key":"10.1016\/j.intimp.2011.05.008_bb0930","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0014-4894(03)00097-3","article-title":"Expression of cysteine proteinase type I and II of Leishmania infantum and their recognition by sera during canine and human visceral leishmaniasis","volume":"103","author":"Rafati","year":"2003","journal-title":"Exp Parasitol"},{"issue":"2","key":"10.1016\/j.intimp.2011.05.008_bb0935","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/j.1365-2249.1997.tb08318.x","article-title":"Biochemical analysis and immunogenicity of Leishmania major amastigote fractions in cutaneous leishmaniasis","volume":"110","author":"Rafati","year":"1997","journal-title":"Clin Exp Immunol"},{"issue":"6","key":"10.1016\/j.intimp.2011.05.008_bb0940","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.1128\/IAI.73.6.3787-3789.2005","article-title":"Recombinant cysteine proteinase from Leishmania (Leishmania) chagasi implicated in human and dog T-cell responses","volume":"73","author":"da Costa Pinheiro","year":"2005","journal-title":"Infect Immun"},{"issue":"3","key":"10.1016\/j.intimp.2011.05.008_bb0945","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.0141-9838.2004.00691.x","article-title":"Th1 and Th2 immunological profile induced by cysteine proteinase in murine leishmaniasis","volume":"26","author":"Alves","year":"2004","journal-title":"Parasite Immunol"},{"issue":"5","key":"10.1016\/j.intimp.2011.05.008_bb0950","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.vaccine.2007.11.044","article-title":"Immunization with the cysteine proteinase Ldccys1 gene from Leishmania (Leishmania) chagasi and the recombinant Ldccys1 protein elicits protective immune responses in a murine model of visceral leishmaniasis","volume":"26","author":"Ferreira","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2011.05.008_bb0955","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/0092-8674(86)90693-8","article-title":"Speculations on the functions of the major heat shock and glucose-regulated proteins","volume":"46","author":"Pehlam","year":"1986","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2011.05.008_bb0960","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/0092-8674(89)90059-7","article-title":"S. cerevisiae encodes an essential protein homologous in sequence and function to mammalian BiP","volume":"57","author":"Normington","year":"1989","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2011.05.008_bb0965","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/0092-8674(89)90058-5","article-title":"KAR2 a karyogamy gene is a yeast homolog of mammalian BiP\/grp78","volume":"57","author":"Rose","year":"1989","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2011.05.008_bb0970","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1128\/IAI.62.6.2499-2507.1994","article-title":"Molecular cloning and characterization of the 78-kilodalton glucose-regulated protein of Trypanosoma cruzi","volume":"62","author":"Tibbetts","year":"1994","journal-title":"Infect Immunol"},{"issue":"5733","key":"10.1016\/j.intimp.2011.05.008_bb0975","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1126\/science.1112680","article-title":"The genome of the kinetoplastid parasite Leishmania major","volume":"309","author":"Ivens","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.intimp.2011.05.008_bb0980","unstructured":"Peacock CS, Seeger K, Harris D, Murphy L, Ruiz JC, Quail MA, et al. Analysis of genome architecture and content between three Leishmania species causing diverse human disease reveals only a small subset of species-specific genes (Unpublished data)."},{"issue":"7","key":"10.1016\/j.intimp.2011.05.008_bb0985","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/ng2053","article-title":"Comparative genomic analysis of three Leishmania species that cause diverse human disease","volume":"39","author":"Peacock","year":"2007","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.intimp.2011.05.008_bb0990","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0167-4838(01)00240-0","article-title":"Molecular and immunological characterisation of the glucose regulated protein 78 of Leishmania donovani","volume":"1549","author":"Jensen","year":"2001","journal-title":"Biochim Biophys Acta"},{"issue":"4","key":"10.1016\/j.intimp.2011.05.008_bb0995","first-page":"BR117","article-title":"Serodiagnostic and immunoprophylactic potential of a 78kDa protein of Leishmania donovani of Indian origin","volume":"8","author":"Mukherjee","year":"2002","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.intimp.2011.05.008_bb1000","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.1016\/j.vaccine.2010.01.015","article-title":"Enhanced efficacy and immunogenicity of 78kDa antigen formulated in various adjuvants against murine visceral leishmaniasis","volume":"28","author":"Nagill","year":"2010","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.intimp.2011.05.008_bb1005","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.1128\/IAI.63.9.3559-3566.1995","article-title":"Leishmania pifanoi amastigote antigens protect mice against cutaneous leishmaniasis","volume":"63","author":"Soong","year":"1995","journal-title":"Infect Immun"},{"issue":"5","key":"10.1016\/j.intimp.2011.05.008_bb1010","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1128\/IAI.01528-07","article-title":"Leishmania pifanoi proteoglycolipid complex P8 induces macrophage cytokine production through Toll-like receptor 4","volume":"76","author":"Whitaker","year":"2008","journal-title":"Infect Immun"},{"issue":"6","key":"10.1016\/j.intimp.2011.05.008_bb1015","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1128\/IAI.73.6.3823-3827.2005","article-title":"CD4+ T cells play a dominant role in protection against new world leishmaniasis induced by vaccination with the P-4 amastigote antigen","volume":"73","author":"Kar","year":"2005","journal-title":"Infect Immun"},{"issue":"8","key":"10.1016\/j.intimp.2011.05.008_bb1020","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1016\/j.vaccine.2006.10.036","article-title":"Immunogenicity of the P-8 amastigote antigen in the experimental model of canine visceral leishmaniasis","volume":"25","author":"Carrillo","year":"2007","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.intimp.2011.05.008_bb1025","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1006\/expr.1996.0100","article-title":"T-cell responsiveness of American cutaneous leishmaniasis patients to purified Leishmania pifanoi amastigote antigens and Leishmania braziliensis promastigote antigens: immunologic patterns associated with cure","volume":"84","author":"Coutinho","year":"1996","journal-title":"Exp Parasitol"},{"issue":"1","key":"10.1016\/j.intimp.2011.05.008_bb1030","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1046\/j.1365-3024.1998.t01-1-00126.x","article-title":"T cell responses to crude and defined leishmanial antigens in patients from the lower Amazon region of Brazil infected with different species of Leishmania of the subgenera Leishmania and Viannia","volume":"20","author":"Silveira","year":"1998","journal-title":"Parasite Immunol"},{"issue":"7","key":"10.1016\/j.intimp.2011.05.008_bb1035","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1128\/IAI.66.7.3100-3105.1998","article-title":"Leishmania pifanoi amastigote antigen P-4: epitopes involved in T-cell responsiveness in human cutaneous leishmaniasis","volume":"66","author":"Haberer","year":"1998","journal-title":"Infect Immun"},{"issue":"48","key":"10.1016\/j.intimp.2011.05.008_bb1040","doi-asserted-by":"crossref","first-page":"37789","DOI":"10.1074\/jbc.M002149200","article-title":"The immunologically protective P-4 antigen of Leishmania amastigotes: a developmentally regulated single strand-specific nuclease associated with the endoplasmic reticulum","volume":"275","author":"Kar","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.intimp.2011.05.008_bb1045","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0264-410X(01)00322-X","article-title":"Immunization with A2 protein results in a mixed Th1\/Th2 and a humoral response which protects mice against Leishmania donovani infections","volume":"20","author":"Ghosh","year":"2001","journal-title":"Vaccine"},{"issue":"35","key":"10.1016\/j.intimp.2011.05.008_bb1050","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1016\/j.vaccine.2008.05.091","article-title":"Epitope mapping and protective immunity elicited by adenovirus expressing the Leishmania amastigote specific A2 antigen: correlation with IFN-\u03b3 and cytolytic activity by CD8+ T cells","volume":"26","author":"Resende","year":"2008","journal-title":"Vaccine"},{"issue":"46","key":"10.1016\/j.intimp.2011.05.008_bb1055","doi-asserted-by":"crossref","first-page":"5888","DOI":"10.1016\/j.vaccine.2008.05.095","article-title":"Protective immunity against challenge with Leishmania (Leishmania) chagasi in beagle dogs vaccinated with recombinant A2 protein","volume":"26","author":"Fernandes","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2011.05.008_bb1060","doi-asserted-by":"crossref","first-page":"7064","DOI":"10.4049\/jimmunol.165.12.7064","article-title":"Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis","volume":"165","author":"Stager","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/j.intimp.2011.05.008_bb1065","series-title":"Proceedings of the Third World Congress on Leishmaniosis Palermo-Terrasini (Italy)","first-page":"178","article-title":"Immunization with H1 and HASPB1 Leishmania proteins protect dogs against experimental canine leishmaniasis","author":"Moreno","year":"2005"},{"issue":"29","key":"10.1016\/j.intimp.2011.05.008_bb1070","doi-asserted-by":"crossref","first-page":"5290","DOI":"10.1016\/j.vaccine.2007.05.010","article-title":"Immunization with H1 HASPB1 and MML Leishmania proteins in a vaccine trial against experimental canine leishmaniasis","volume":"25","author":"Moreno","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2011.05.008_bb1075","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1128\/IAI.63.5.2062-2069.1995","article-title":"A recombinant Leishmania chagasi antigen that stimulates cellular immune responses in infected mice","volume":"63","author":"Wilson","year":"1995","journal-title":"Infect Immun"},{"issue":"3","key":"10.1016\/j.intimp.2011.05.008_bb1080","first-page":"320a","article-title":"A recombinant bcg vaccine expressing the Leishmania chagasi antigen lcr1","volume":"44","author":"Streit","year":"1996","journal-title":"J Invest Med"},{"issue":"1","key":"10.1016\/j.intimp.2011.05.008_bb1085","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1006\/expr.1999.4459","article-title":"BCG expressing LCR1 of Leishmania chagasi induces protective immunity in susceptible mice","volume":"94","author":"Streit","year":"2000","journal-title":"Exp Parasitol"},{"issue":"8","key":"10.1016\/j.intimp.2011.05.008_bb1090","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1086\/378677","article-title":"Protection against cutaneous leishmaniasis in outbred vervet monkeys using a recombinant histone H1 antigen","volume":"188","author":"Masina","year":"2003","journal-title":"J Infect Dis"},{"key":"10.1016\/j.intimp.2011.05.008_bb1095","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/S0264-410X(99)00340-0","article-title":"The protective capacities of histone H1 against experimental murine cutaneous leishmaniasis","volume":"18","author":"Solioz","year":"1999","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.intimp.2011.05.008_bb1100","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1006\/expr.1999.4453","article-title":"Leishmania donovani: characterization and expression of ORFF a gene amplified from the LDI locus","volume":"93","author":"Ghosh","year":"1999","journal-title":"Exp Parasitol"},{"issue":"1\u20132","key":"10.1016\/j.intimp.2011.05.008_bb1105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.gene.2008.01.011","article-title":"Characterization and localization of ORFF gene from the LD1 locus of Leishmania donovani","volume":"416","author":"Jain","year":"2008","journal-title":"Gene"},{"key":"10.1016\/j.intimp.2011.05.008_bb1110","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0264-410X(00)00207-3","article-title":"Immunization with recombinant LD1 antigens protects against experimental leishmaniasis","volume":"19","author":"Dole","year":"2000","journal-title":"Vaccine"},{"issue":"23\u201324","key":"10.1016\/j.intimp.2011.05.008_bb1115","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1016\/j.vaccine.2004.02.007","article-title":"Immunostimulatory oligodeoxynucleotides are potent enhancers of protective immunity in mice immunized with recombinant ORFF leishmanial antigen","volume":"22","author":"Tewary","year":"2004","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.intimp.2011.05.008_bb1120","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1086\/430348","article-title":"A heterologous prime-boost vaccination regimen using ORFF DNA and recombinant ORFF protein confers protective immunity against experimental visceral leishmaniasis","volume":"191","author":"Tewary","year":"2005","journal-title":"J Infect Dis"},{"issue":"13","key":"10.1016\/j.intimp.2011.05.008_bb1125","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1016\/j.vaccine.2005.11.058","article-title":"Co-administration of IL-12 DNA with rORFF antigen confers long-term protective immunity against experimental visceral leishmaniaisis","volume":"24","author":"Tewary","year":"2006","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.intimp.2011.05.008_bb1130","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1093\/infdis\/157.6.1212","article-title":"Use of purified parasite proteins from Leishmania donovani for the rapid serodiagnosis of visceral leishmaniasis","volume":"157","author":"Jaffe","year":"1988","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.intimp.2011.05.008_bb1135","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/0165-2478(95)02436-0","article-title":"Identification of the Leishmania infantum P0 ribosomal protein epitope in canine visceral leishmaniasis","volume":"48","author":"Soto","year":"1995","journal-title":"Immunol Lett"},{"issue":"9","key":"10.1016\/j.intimp.2011.05.008_bb1140","doi-asserted-by":"crossref","first-page":"5842","DOI":"10.1128\/IAI.73.9.5842-5852.2005","article-title":"Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL\/6 mice but does not prevent progressive disease in BALB\/c mice","volume":"73","author":"Iborra","year":"2005","journal-title":"Infect Immun"},{"issue":"10\u201311","key":"10.1016\/j.intimp.2011.05.008_bb1145","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.micinf.2008.06.002","article-title":"Vaccination with the Leishmania major ribosomal proteins plus CpG oligodeoxynucleotides induces protection against experimental cutaneous leishmaniasis in mice","volume":"10","author":"Iborra","year":"2008","journal-title":"Microbes Infect"},{"issue":"11","key":"10.1016\/j.intimp.2011.05.008_bb1150","doi-asserted-by":"crossref","first-page":"4893","DOI":"10.1128\/IAI.62.11.4893-4899.1994","article-title":"The kinetoplastid membrane protein 11 of Leishmania donovani and African trypanosomes is a potent stimulator of T-lymphocyte proliferation","volume":"62","author":"Tolson","year":"1994","journal-title":"Infect Immun"},{"issue":"3","key":"10.1016\/j.intimp.2011.05.008_bb1155","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0165-2478(99)00146-7","article-title":"The humoral immune response to the kinetoplastid membrane protein-11 in patients with American leishmaniasis and Chagas disease: prevalence of IgG subclasses and mapping of epitopes","volume":"70","author":"Trujillo","year":"2000","journal-title":"Immunol Lett"},{"issue":"5","key":"10.1016\/j.intimp.2011.05.008_bb1160","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s00436-007-0844-9","article-title":"Leishmania major infection in susceptible and resistant mice elicit a differential humoral response against a total soluble fraction and defined recombinant antigens of the parasite","volume":"102","author":"Iniesta","year":"2008","journal-title":"Parasitol Res"},{"issue":"1","key":"10.1016\/j.intimp.2011.05.008_bb1165","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1046\/j.1365-3083.1998.00370.x","article-title":"Humoral and cellular immune responses to synthetic peptides of the Leishmania donovani kinetoplastid membrane protein-11","volume":"48","author":"Jensen","year":"1998","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.intimp.2011.05.008_bb1170","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1016\/j.vaccine.2008.01.042","article-title":"Immunogenicity of HSP-70 KMP-11 and PFR-2 leishmanial antigens in the experimental model of canine visceral leishmaniasis","volume":"26","author":"Carrillo","year":"2008","journal-title":"Vaccine"},{"issue":"3\u20134","key":"10.1016\/j.intimp.2011.05.008_bb1175","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0264-410X(01)00341-3","article-title":"Attenuated Toxoplasma gondii ts-4 mutants engineered to express the Leishmania antigen KMP-11 elicit a specific immune response in BALB\/c mice","volume":"20","author":"Ramirez","year":"2001","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.intimp.2011.05.008_bb1180","doi-asserted-by":"crossref","first-page":"5956","DOI":"10.1128\/IAI.00944-07","article-title":"Hybrid cell vaccination resolves Leishmania donovani infection by eliciting a strong CD8+ cytotoxic T-lymphocyte response with concomitant suppression of interleukin-10 (IL-10) but not IL-4 or IL-13","volume":"75","author":"Basu","year":"2007","journal-title":"Infect Immun"},{"issue":"8","key":"10.1016\/j.intimp.2011.05.008_bb1185","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.vaccine.2004.07.044","article-title":"Protective immunogenicity of the paraflagellar rod protein 2 of Leishmania mexicana","volume":"23","author":"Saravia","year":"2005","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.intimp.2011.05.008_bb1190","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1002\/pmic.200600725","article-title":"Proteomic approach for identification and characterization of novel immunostimulatory proteins from soluble antigens of Leishmania donovani promastigotes","volume":"7","author":"Gupta","year":"2007","journal-title":"Proteomics"},{"issue":"37","key":"10.1016\/j.intimp.2011.05.008_bb1195","doi-asserted-by":"crossref","first-page":"4813","DOI":"10.1016\/j.vaccine.2008.06.102","article-title":"Induction of Th1-type cellular responses in cured\/exposed Leishmania-infected patients and hamsters against polyproteins of soluble Leishmania donovani promastigotes ranging from 89.9 to 97.1 kDa","volume":"26","author":"Kumari","year":"2008","journal-title":"Vaccine"},{"issue":"45","key":"10.1016\/j.intimp.2011.05.008_bb1200","doi-asserted-by":"crossref","first-page":"5700","DOI":"10.1016\/j.vaccine.2008.08.021","article-title":"Th1-stimulatory polyproteins of soluble Leishmania donovani promastigotes ranging from 89.9 to 97.1kDa offers long-lasting protection against experimental visceral leishmaniasis","volume":"26","author":"Kumari","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2011.05.008_bb1205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0165-2427(02)00315-X","article-title":"A Leishmania infantum multi-component antigenic protein mixed with live BCG confers protection to dogs experimentally infected with L infantum","volume":"92","author":"Molano","year":"2003","journal-title":"Vet Immunol Immunopathol"},{"issue":"6\u20137","key":"10.1016\/j.intimp.2011.05.008_bb1210","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.0141-9838.2004.00711.x","article-title":"Adjuvant guided polarization of the immune humoral response against a protective multicomponent antigenic protein (Q) from Leishmania infantum A CpG + Q mix protects Balb\/c mice from infection","volume":"26","author":"Parody","year":"2004","journal-title":"Parasite Immunol"},{"key":"10.1016\/j.intimp.2011.05.008_bb1215","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1128\/IAI.66.7.3279-3289.1998","article-title":"Human and murine immune responses to a novel Leishmania major recombinant protein encoded by members of a multicopy gene family","volume":"66","author":"Webb","year":"1998","journal-title":"Infect Immun"},{"issue":"9","key":"10.1016\/j.intimp.2011.05.008_bb1220","doi-asserted-by":"crossref","first-page":"5270","DOI":"10.1128\/IAI.69.9.5270-5277.2001","article-title":"Potent stimulation of the innate immune system by a Leishmania brasiliensis recombinant protein","volume":"69","author":"Borges","year":"2001","journal-title":"Infect Immun"},{"issue":"6","key":"10.1016\/j.intimp.2011.05.008_bb1225","doi-asserted-by":"crossref","first-page":"4103","DOI":"10.1128\/IAI.69.6.4103-4108.2001","article-title":"Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease","volume":"69","author":"Campos-Neto","year":"2001","journal-title":"Infect Immun"},{"issue":"2","key":"10.1016\/j.intimp.2011.05.008_bb1230","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.exppara.2006.07.002","article-title":"Leishmania major: immune response in BALB\/c mice immunized with stress-inducible protein 1 encapsulated in liposomes","volume":"115","author":"Badiee","year":"2007","journal-title":"Exp Parasitol"},{"issue":"4","key":"10.1016\/j.intimp.2011.05.008_bb1235","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1128\/CVI.00413-07","article-title":"Coencapsulation of CpG oligodeoxynucleotides with recombinant Leishmania major stress-inducible protein 1 in liposome enhances immune response and protection against leishmaniasis in immunized BALB\/c mice","volume":"15","author":"Badiee","year":"2008","journal-title":"Clin Vaccine Immunol"},{"issue":"8","key":"10.1016\/j.intimp.2011.05.008_bb1240","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1128\/IAI.70.8.4215-4225.2002","article-title":"Immunization with a polyprotein vaccine consisting of the T-cell antigens thiol-specific antioxidant Leishmania major stress-inducible protein 1 and Leishmania elongation initiation factor protects against leishmaniasis","volume":"70","author":"Coler","year":"2002","journal-title":"Infect Immun"},{"issue":"27\u201328","key":"10.1016\/j.intimp.2011.05.008_bb1245","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1016\/S0264-410X(02)00302-X","article-title":"Protective efficacy of a tandemly linked multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL\u00ae adjuvant","volume":"20","author":"Skeiky","year":"2002","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.intimp.2011.05.008_bb1250","doi-asserted-by":"crossref","first-page":"4648","DOI":"10.1128\/IAI.00394-07","article-title":"Leish-111f a recombinant polyprotein vaccine that protects against visceral leishmaniasis by elicitation of CD4+ T cells","volume":"75","author":"Coler","year":"2007","journal-title":"Infect Immun"},{"issue":"8","key":"10.1016\/j.intimp.2011.05.008_bb1255","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1086\/507708","article-title":"Immunotherapy for drug-refractory mucosal leishmaniasis","volume":"194","author":"Badaro","year":"2006","journal-title":"J Infect Dis"},{"issue":"9","key":"10.1016\/j.intimp.2011.05.008_bb1260","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1128\/CVI.00060-07","article-title":"Testing of four Leishmania vaccine candidates in a mouse model of infection with Leishmania (Viannia) braziliensis the main causative agent of cutaneous leishmaniasis in the New World","volume":"14","author":"Salay","year":"2007","journal-title":"Clin Vaccine Immunol"},{"issue":"5\u20136","key":"10.1016\/j.intimp.2011.05.008_bb1265","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1051\/vetres:2005033","article-title":"Immunogenicity in dogs of three recombinant antigens (TSA LeIF and LmSTI1) potential vaccine candidates for canine visceral leishmaniasis","volume":"36","author":"Fujiwara","year":"2005","journal-title":"Vet Res"},{"issue":"45","key":"10.1016\/j.intimp.2011.05.008_bb1270","doi-asserted-by":"crossref","first-page":"5245","DOI":"10.1016\/j.vaccine.2005.07.001","article-title":"Failure of a multi-subunit recombinant leishmanial vaccine (MML) to protect dogs from Leishmania infantum infection and to prevent disease progression in infected animals","volume":"23","author":"Gradoni","year":"2005","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.intimp.2011.05.008_bb1275","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/j.vaccine.2008.01.026","article-title":"Evaluation of an immunochemotherapeutic protocol constituted of N-methyl meglumine antimoniate (Glucantime\u00ae) and the recombinant Leish-110f\u00ae + MPL-SE\u00ae vaccine to treat canine visceral leishmaniasis","volume":"26","author":"Miret","year":"2008","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.intimp.2011.05.008_bb1280","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1089\/hum.2006.17.1051","article-title":"DNA vaccines: recent developments and future possibilities","volume":"17","author":"Liu","year":"2006","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.intimp.2011.05.008_bb1285","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0065-308X(08)60152-9","article-title":"DNA vaccines: technology and application as anti-parasite and anti-microbial agents","volume":"42","author":"Alarcon","year":"1999","journal-title":"Adv Parasitol"},{"key":"10.1016\/j.intimp.2011.05.008_bb1290","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/sj.gt.3301117","article-title":"The promise of nucleic acid vaccines","volume":"7","author":"Restifo","year":"2000","journal-title":"Gene Ther"},{"key":"10.1016\/j.intimp.2011.05.008_bb1295","first-page":"173","article-title":"Protection against leishmaniasis by injection of DNA encoding a major surface glycoprotein gp63 of L major","volume":"84","author":"Xu","year":"1995","journal-title":"Immunology"},{"key":"10.1016\/j.intimp.2011.05.008_bb1300","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/S0264-410X(00)00398-4","article-title":"Immunization with DNA encoding Leishmania infantum protein papLe22 decreases the frequency of parasitemic episodes in infected hamsters","volume":"19","author":"Fragaki","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2011.05.008_bb1305","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1016\/S0264-410X(01)00081-0","article-title":"A protective cocktail vaccine against murine cutaneous leishmaniasis with DNA encoding cysteine proteinases of Leishmania major","volume":"19","author":"Rafati","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2011.05.008_bb1310","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1128\/IAI.70.6.2828-2836.2002","article-title":"Vaccination with plasmid DNA encoding TSA\/LmSTI1 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB\/c mice","volume":"70","author":"Campos-Neto","year":"2002","journal-title":"Infect Immun"},{"issue":"13\u201314","key":"10.1016\/j.intimp.2011.05.008_bb1315","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1016\/j.vaccine.2003.10.046","article-title":"A comparative evaluation of different DNA vaccine candidates against experimental murine due to L major","volume":"22","author":"Ahmed","year":"2004","journal-title":"Vaccine"},{"issue":"29\u201330","key":"10.1016\/j.intimp.2011.05.008_bb1320","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1016\/j.vaccine.2004.04.015","article-title":"Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniasis","volume":"22","author":"Iborra","year":"2004","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.intimp.2011.05.008_bb1325","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1128\/IAI.73.2.812-819.2005","article-title":"Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis","volume":"73","author":"Aguilar-Be","year":"2005","journal-title":"Infect Immun"},{"issue":"46","key":"10.1016\/j.intimp.2011.05.008_bb1330","doi-asserted-by":"crossref","first-page":"7962","DOI":"10.1016\/j.vaccine.2007.08.023","article-title":"Vaccination with plasmid DNA encoding KMPII TRYP LACK and GP63 does not protect dogs against Leishmania infantum experimental challenge","volume":"25","author":"Rodriguez-Cortes","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2011.05.008_bb1335","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/S0264-410X(02)00352-3","article-title":"Vaccination with DNA encoding ORFF antigen confers protective immunity in mice infected with Leishmania donovani","volume":"21","author":"Sukumaran","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2011.05.008_bb1340","series-title":"Nucleoside hydrolase DNA vaccine against visceral leishmaniasis. Vaccine Congress Celebrating 25years of publication, 9\u201311 December 2007, the Netherlands, vol 1","first-page":"167","author":"Borja-Cabrera","year":"2007"},{"key":"10.1016\/j.intimp.2011.05.008_bb1345","doi-asserted-by":"crossref","first-page":"6270","DOI":"10.1128\/IAI.71.11.6270-6278.2003","article-title":"DNA immunization with the gene encoding P4 nuclease of Leishmania amazonensis protects mice against cutaneous leishmaniasis","volume":"71","author":"Campbell","year":"2003","journal-title":"Infect Immun"},{"issue":"7\u20138","key":"10.1016\/j.intimp.2011.05.008_bb1350","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/S0264-410X(01)00427-3","article-title":"A heterologous prime-boost regime using DNA and recombinant vaccinia virus expressing the Leishmania infantum P36\/LACK antigen protects BALB\/c mice from cutaneous leishmaniasis","volume":"20","author":"Gonzalo","year":"2002","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.intimp.2011.05.008_bb1355","first-page":"23","article-title":"Prime-boost immunization strategies for infectious diseases","volume":"4","author":"McShane","year":"2002","journal-title":"Curr Opin Mol Ther"},{"issue":"19\u201320","key":"10.1016\/j.intimp.2011.05.008_bb1360","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1016\/S0264-410X(03)00032-X","article-title":"Protection in dogs against visceral leishmaniasis caused by Leishmania infantum is achieved by immunization with a heterologous prime-boost regime using DNA vaccine and vaccinia recombinant vectors expressing LACK","volume":"21","author":"Ramiro","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2011.05.008_bb1365","first-page":"168","author":"Souza","year":"2007"},{"issue":"11","key":"10.1016\/j.intimp.2011.05.008_bb1370","doi-asserted-by":"crossref","first-page":"7160","DOI":"10.4049\/jimmunol.174.11.7160","volume":"174","author":"Basu","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.intimp.2011.05.008_bb1375","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1016\/j.vaccine.2005.02.009","article-title":"Protective vaccination against canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and Type II of L infantum","volume":"23","author":"Rafati","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2011.05.008_bb1380","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1016\/0264-410X(94)90079-5","article-title":"Genetic vaccination against leishmaniasis","volume":"12","author":"Xu","year":"1994","journal-title":"Vaccine"},{"issue":"13","key":"10.1016\/j.intimp.2011.05.008_bb1385","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1089\/hum.1998.9.13-1899","article-title":"Genetic immunization with glycoprotein 63 cDNA results in a helper T cell type 1 immune response and protection in a murine model of leishmaniasis","volume":"9","author":"Walker","year":"1998","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.intimp.2011.05.008_bb1390","first-page":"135","article-title":"Comparative study of DNA vaccines encoding various antigens against Leishmania mexicana","volume":"104","author":"Dumonteil","year":"2000","journal-title":"Dev Boil"},{"issue":"17\u201318","key":"10.1016\/j.intimp.2011.05.008_bb1395","first-page":"2170","article-title":"DNA vaccines induce partial protection against Leishmania mexicana","volume":"21","author":"Dumonteil","year":"2003","journal-title":"Vaccine"},{"issue":"46\u201347","key":"10.1016\/j.intimp.2011.05.008_bb1400","doi-asserted-by":"crossref","first-page":"5372","DOI":"10.1016\/j.vaccine.2005.05.037","article-title":"Aluminium phosphate potentiates the efficacy of DNA vaccines against Leishmania mexicana","volume":"23","author":"Rosado-Vallado","year":"2005","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.intimp.2011.05.008_bb1405","doi-asserted-by":"crossref","first-page":"3949","DOI":"10.4049\/jimmunol.160.8.3949","article-title":"Induction of a Th1 immune response and simultaneous lack of activation of a Th2 response are required for generation of immunity to leishmaniasis","volume":"160","author":"Sjolander","year":"1998","journal-title":"J Immunol"},{"issue":"26","key":"10.1016\/j.intimp.2011.05.008_bb1410","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1016\/S0264-410X(00)00109-2","article-title":"Therapy of murine cutaneous leishmaniasis by DNA vaccination","volume":"18","author":"Handman","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2011.05.008_bb1415","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1016\/S0264-410X(01)00132-3","article-title":"Paradoxical effects of IL-12 in leishmaniasis in the presence and absence of vaccinating antigen","volume":"19","author":"Noormohammadi","year":"2001","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.intimp.2011.05.008_bb1420","doi-asserted-by":"crossref","first-page":"915","DOI":"10.4049\/jimmunol.165.2.915","article-title":"Requirements for the maintenance of Th1 immunity in vivo following DNA vaccination: a potential immunoregulatory role for CD8+ T cells","volume":"165","author":"Gurunathan","year":"2000","journal-title":"J Immunol"},{"issue":"12","key":"10.1016\/j.intimp.2011.05.008_bb1425","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1016\/j.vaccine.2006.11.060","article-title":"Intranasal delivery of naked DNA encoding the LACK antigen leads to protective immunity against visceral leishmaniasis in mice","volume":"25","author":"Gomes","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2011.05.008_bb1430","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00436-005-0008-8","article-title":"Intramuscular immunization with p36(LACK) DNA vaccine induces IFN-gamma production but does not protect BALB\/c mice against Leishmania chagasi intravenous challenge","volume":"98","author":"Marques-da-Silva","year":"2005","journal-title":"Parasitol Res"},{"key":"10.1016\/j.intimp.2011.05.008_bb1435","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.1128\/IAI.69.8.4719-4725.2001","article-title":"Leishmania donovani p36 (LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis","volume":"69","author":"Melby","year":"2001","journal-title":"Infect Immun"},{"issue":"1","key":"10.1016\/j.intimp.2011.05.008_bb1440","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.vaccine.2008.10.013","article-title":"DNA based vaccination with a cocktail of plasmids encoding immunodominant Leishmania (Leishmania) major antigens confers full protection in BALB\/c mice","volume":"27","author":"Ahmed","year":"2009","journal-title":"Vaccine"},{"issue":"22","key":"10.1016\/j.intimp.2011.05.008_bb1445","doi-asserted-by":"crossref","first-page":"4863","DOI":"10.1016\/j.vaccine.2006.03.005","article-title":"Immunotherapy against visceral leishmaniasis with the nucleoside hydrolase-DNA vaccine of L. donovani","volume":"24","author":"Gamboa-Leon","year":"2006","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.intimp.2011.05.008_bb1450","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.vaccine.2008.12.053","article-title":"KMP-11 DNA immunization significantly protects against L. donovani infection but requires exogenous IL-12 as an adjuvant for comparable protection against L. major","volume":"27","author":"Bhaumik","year":"2009","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.intimp.2011.05.008_bb1455","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.micinf.2007.05.012","article-title":"Evaluation of immune responses and protection induced by A2 and nucleoside hydrolase (NH) DNA vaccines against Leishmania chagasi and Leishmania amazonensis experimental infections","volume":"9","author":"Zanin","year":"2007","journal-title":"Microbes Infect"},{"key":"10.1016\/j.intimp.2011.05.008_bb1460","doi-asserted-by":"crossref","first-page":"5122","DOI":"10.4049\/jimmunol.166.8.5122","article-title":"The potency and durability of DNA- and protein-based vaccines against Leishmania major evaluated using low-dose intradermal challenge","volume":"166","author":"Mendez","year":"2001","journal-title":"J Immunol"},{"issue":"11","key":"10.1016\/j.intimp.2011.05.008_bb1465","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1016\/j.vaccine.2005.10.052","article-title":"Immunogenicity of a multicomponent DNA vaccine against visceral leishmaniasis in dogs","volume":"24","author":"Saldarriaga","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2011.05.008_bb1470","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.virol.2005.12.029","article-title":"Immunization of rhesus macaques with a polyvalent DNA prime\/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype","volume":"348","author":"Pal","year":"2006","journal-title":"Virology"},{"key":"10.1016\/j.intimp.2011.05.008_bb1475","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.vaccine.2007.12.024","article-title":"Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers","volume":"26","author":"Wang","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2011.05.008_bb1480","doi-asserted-by":"crossref","first-page":"5872","DOI":"10.1016\/j.vaccine.2006.04.065","article-title":"Passive immunotherapy of Bacillus anthracis pulmonary infection in mice with antisera produced by DNA immunization","volume":"24","author":"Herrmann","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2011.05.008_bb1485","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/j.vaccine.2004.10.013","article-title":"Augmented humoral and cellular immune responses of a hepatitis B DNA vaccine encoding HBsAg by protein boosting","volume":"23","author":"Xiao-wen","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2011.05.008_bb1490","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S1286-4579(02)00077-1","article-title":"The combination of DNA vectors expressing IL-12+IL-18 elicits high protective immune response against cutaneous leishmaniasis after priming with DNA-p36\/LACK and the cytokines followed by a booster with a vaccinia virus recombinant expressing p36\/LACK","volume":"5","author":"Tapia","year":"2003","journal-title":"Microbes Infect"},{"key":"10.1016\/j.intimp.2011.05.008_bb1495","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0264-410X(02)00450-4","article-title":"DNA vaccination with linear minimalistic (MIDGE) vectors confers protection against Leishmania major infection in mice","volume":"21","author":"Lopez-Fuertes","year":"2002","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.intimp.2011.05.008_bb1500","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.micinf.2005.10.004","article-title":"MVA-LACK as a safe and efficient vector for vaccination against leishmaniasis","volume":"8","author":"Perez-Jimenez","year":"2006","journal-title":"Microbes Infect"},{"key":"10.1016\/j.intimp.2011.05.008_bb1505","doi-asserted-by":"crossref","first-page":"5286","DOI":"10.1128\/IAI.73.8.5286-5289.2005","article-title":"Heterologous prime-boost vaccination with the LACK antigen protects against murine visceral leishmaniasis","volume":"73","author":"Dondji","year":"2005","journal-title":"Infect Immun"},{"key":"10.1016\/j.intimp.2011.05.008_bb1510","doi-asserted-by":"crossref","first-page":"4924","DOI":"10.1128\/IAI.72.8.4924-4928.2004","article-title":"DNA-Salmonella enterica serovar Typhimurium primer-booster vaccination biases towards T helper 1 responses and enhances protection against Leishmania major infection in mice","volume":"72","author":"Lange","year":"2004","journal-title":"Infect Immun"},{"issue":"3","key":"10.1016\/j.intimp.2011.05.008_bb1515","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.vaccine.2007.11.021","article-title":"Heterologous prime-boost vaccination with a non-replicative vaccinia recombinant vector expressing LACK confers protection against canine visceral leishmaniasis with a predominant Th1-specific immune response","volume":"26","author":"Ramos","year":"2008","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.intimp.2011.05.008_bb1520","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.vaccine.2008.11.094","article-title":"A prime\/boost DNA\/Modified vaccinia virus Ankara vaccine expressing recombinant Leishmania DNA encoding TRYP is safe and immunogenic in outbred dogs the reservoir of zoonotic visceral leishmaniasis","volume":"27","author":"Carson","year":"2009","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.intimp.2011.05.008_bb1525","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1016\/j.vaccine.2005.11.011","article-title":"Prime-boost vaccination using cysteine proteinases type I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis","volume":"24","author":"Rafati","year":"2006","journal-title":"Vaccine"},{"issue":"46","key":"10.1016\/j.intimp.2011.05.008_bb1530","doi-asserted-by":"crossref","first-page":"5822","DOI":"10.1016\/j.vaccine.2008.08.065","article-title":"Cysteine proteinase type III is protective against Leishmania infantum infection in BALB\/c mice and highly antigenic in visceral leishmaniasis individuals","volume":"26","author":"Khoshgoo","year":"2008","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.intimp.2011.05.008_bb1535","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.exppara.2007.10.004","article-title":"Leishmania infantum: prime boost vaccination with C-terminal extension of cysteine proteinase type I displays both type 1 and 2 immune signatures in BALB\/c mice","volume":"118","author":"Rafati","year":"2008","journal-title":"Exp Parasitol"},{"issue":"11","key":"10.1016\/j.intimp.2011.05.008_bb1540","doi-asserted-by":"crossref","first-page":"6562","DOI":"10.1128\/IAI.71.11.6562-6572.2003","article-title":"The Leishmania infantum acidic ribosomal protein P0 administered as a DNA vaccine confers protective immunity to Leishmania major infection in BALB\/c mice","volume":"71","author":"Iborra","year":"2003","journal-title":"Infect Immun"},{"key":"10.1016\/j.intimp.2011.05.008_bb1545","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0169-4758(98)01362-3","article-title":"How do protozoan parasites survive inside macrophages?","volume":"15","author":"Bogdan","year":"1999","journal-title":"Parasitol Today"},{"key":"10.1016\/j.intimp.2011.05.008_bb1550","series-title":"Foundations of parasitology","first-page":"68","author":"Roberts","year":"1995"},{"key":"10.1016\/j.intimp.2011.05.008_bb1555","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0925-4439(99)00065-4","article-title":"Glycoconjugates in Leishmania infectivity","volume":"1455","author":"Descoteaux","year":"1999","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.intimp.2011.05.008_bb1560","doi-asserted-by":"crossref","first-page":"4676","DOI":"10.1021\/bi00014a022","article-title":"Potent inhibition of viral fusion by the lipophosphoglycan of Leishmania donovani","volume":"34","author":"Miao","year":"1995","journal-title":"Biochemistry"},{"key":"10.1016\/j.intimp.2011.05.008_bb1565","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1006\/exmp.2002.2418","article-title":"Parasitic adaptive mechanisms in infection by Leishmania","volume":"72","author":"Cunningham","year":"2002","journal-title":"Exp Mol Pathol"},{"key":"10.1016\/j.intimp.2011.05.008_bb1570","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/00062752-200001000-00006","article-title":"Leishmania parasites and their ploys to disrupt macrophage activation","volume":"7","author":"Kane","year":"2000","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.intimp.2011.05.008_bb1575","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.4049\/jimmunol.146.8.2747","article-title":"Leishmania donovani lipophosphoglycan selectively inhibits signal transduction in macrophages","volume":"146","author":"Descoteaux","year":"1991","journal-title":"J Immunol"},{"key":"10.1016\/j.intimp.2011.05.008_bb1580","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.4049\/jimmunol.148.4.1188","article-title":"Stimulus-response coupling in monocytes infected with Leishmania: attenuation of calcium transients is related to defective agonist-induced accumulation of inositol phosphates","volume":"148","author":"Olivier","year":"1992","journal-title":"J Immunol"},{"key":"10.1016\/j.intimp.2011.05.008_bb1585","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/0169-4758(93)90105-O","article-title":"The lipophosphoglycan of Leishmania and macrophage protein kinase C","volume":"9","author":"Descoteaux","year":"1993","journal-title":"Parasitol Today"},{"key":"10.1016\/j.intimp.2011.05.008_bb1590","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/0167-5699(94)90176-7","article-title":"Altered cell signaling and mononuclear phagocyte deactivation during intracellular infection","volume":"15","author":"Reiner","year":"1994","journal-title":"Immunol Today"},{"key":"10.1016\/j.intimp.2011.05.008_bb1595","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/375408a0","article-title":"Altered immune responses in mice lacking inducible nitric oxide synthase","volume":"375","author":"Wei","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2011.05.008_bb1600","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1242\/jcs.112.18.2993","article-title":"Leishmania species: models of intracellular parasitism","volume":"112","author":"Alexander","year":"1999","journal-title":"J Cell Sci"},{"key":"10.1016\/j.intimp.2011.05.008_bb1605","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1699-0463.1994.tb04874.x","article-title":"Leishmania major surface protease gp63 interferes with the function of human monocytes and neutrophils in vitro","volume":"102","author":"Sorensen","year":"1994","journal-title":"APMIS"},{"key":"10.1016\/j.intimp.2011.05.008_bb1610","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1128\/IAI.33.2.498-500.1981","article-title":"Cell-mediated immunity in American visceral leishmaniasis: reversible immunosuppression during acute infection","volume":"33","author":"Carvalho","year":"1981","journal-title":"Infect Immun"},{"key":"10.1016\/j.intimp.2011.05.008_bb1615","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1128\/IAI.42.2.702-707.1983","article-title":"Cell-mediated immune response in Indian kala-azar and post-kala-azar dermal leishmaniasis","volume":"42","author":"Haldar","year":"1983","journal-title":"Infect Immun"},{"key":"10.1016\/j.intimp.2011.05.008_bb1620","first-page":"207","article-title":"Immunosuppression in Kenyan visceral leishmaniasis","volume":"51","author":"Ho","year":"1983","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.intimp.2011.05.008_bb1625","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/0035-9203(61)90078-5","article-title":"Immunity in kala-azar","volume":"55","author":"Manson-Bahr","year":"1961","journal-title":"Trans Roy Soc Trop Med Hyg"},{"key":"10.1016\/j.intimp.2011.05.008_bb1630","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/nri933","article-title":"The immunology of susceptibility and resistance to Leishmania major in mice","volume":"2","author":"Sacks","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.intimp.2011.05.008_bb1635","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1006\/cimm.1997.1196","article-title":"Differential effects of LPS and CD40 ligand stimulations on the induction of IL-12 production by dendritic cells and macrophages","volume":"181","author":"Kato","year":"1997","journal-title":"Cell Immunol"},{"key":"10.1016\/j.intimp.2011.05.008_bb1640","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1084\/jem.187.12.2103","article-title":"Murine macrophages secrete interferon gamma upon combined stimulation with interleukin (IL)-12 and IL-18: a novel pathway of autocrine macrophage activation","volume":"187","author":"Munder","year":"1998","journal-title":"J Exp Med"},{"key":"10.1016\/j.intimp.2011.05.008_bb1645","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1006\/smim.1993.1046","article-title":"CD40L: a multi-functional ligand","volume":"5","author":"Armitage","year":"1993","journal-title":"Semin Immunol"},{"issue":"5","key":"10.1016\/j.intimp.2011.05.008_bb1650","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1586\/14760584.2.5.705","article-title":"Vaccines in leishmaniasis: advances in the last five years","volume":"2","author":"Brodskyn","year":"2003","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.intimp.2011.05.008_bb1655","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.4049\/jimmunol.138.6.1926","article-title":"Parasite-accessory cell interactions in murine leishmaniasis. 2. Leishmania donovani suppresses macrophage expression of class-I and class-II major histocompatibility complex gene-products","volume":"138","author":"Reiner","year":"1987","journal-title":"J Immunol"},{"issue":"12","key":"10.1016\/j.intimp.2011.05.008_bb1660","doi-asserted-by":"crossref","first-page":"4330","DOI":"10.1073\/pnas.85.12.4330","article-title":"Kinetics of gamma interferon binding and induction of major histocompatibility complex class II mRNA in Leishmania-infected macrophages","volume":"85","author":"Reiner","year":"1988","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.intimp.2011.05.008_bb1665","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0020-7519(02)00266-7","article-title":"Leishmania (Leishmania) chagasi infection alters the expression of cell adhesion and costimulatory molecules on human monocyte and macrophage","volume":"33","author":"De Almeida","year":"2003","journal-title":"Int J Parasitol"},{"key":"10.1016\/j.intimp.2011.05.008_bb1670","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.4049\/jimmunol.150.5.1857","article-title":"Leishmania major interferes with antigen presentation by infected macrophages","volume":"150","author":"Fruth","year":"1993","journal-title":"J Immunol"},{"key":"10.1016\/j.intimp.2011.05.008_bb1675","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.4049\/jimmunol.151.4.2050","article-title":"Antigen presentation capacity of murine macrophages infected with Leishmania amazonensis amastigotes","volume":"151","author":"Prina","year":"1993","journal-title":"J Immunol"},{"key":"10.1016\/j.intimp.2011.05.008_bb1680","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0952-7915(96)80040-9","article-title":"Invasion, control and persistence of Leishmania parasites","volume":"8","author":"Bogdan","year":"1996","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.intimp.2011.05.008_bb1685","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1006\/cimm.1998.1267","article-title":"Underproduction of interleukin-12 in susceptible mice during progressive leishmaniasis is due to decreased CD40 activity","volume":"184","author":"Heinzel","year":"1998","journal-title":"Cell Immunol"},{"key":"10.1016\/j.intimp.2011.05.008_bb1690","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1084\/jem.170.3.827","article-title":"Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes","volume":"170","author":"Kobayashi","year":"1989","journal-title":"J Exp Med"},{"issue":"17","key":"10.1016\/j.intimp.2011.05.008_bb1695","doi-asserted-by":"crossref","first-page":"6808","DOI":"10.1073\/pnas.87.17.6808","article-title":"Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells","volume":"87","author":"Stern","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.intimp.2011.05.008_bb1700","doi-asserted-by":"crossref","first-page":"92","DOI":"10.4049\/jimmunol.148.1.92","article-title":"Mechanisms of IFN-\u03b3 induction by natural killer cell stimulatory factor (NKSF\/IL-12). Role of transcription and mRNA stability in the synergistic interaction between NKSF and IL-2","volume":"148","author":"Chan","year":"1992","journal-title":"J Immunol"},{"issue":"5107","key":"10.1016\/j.intimp.2011.05.008_bb1705","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1126\/science.8097337","article-title":"IL-12: initiation cytokine for cell-mediated immunity","volume":"260","author":"Scott","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.intimp.2011.05.008_bb1710","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/0167-5699(93)90230-I","article-title":"Interleukin-12 and its role in the generation of TH1 cells","volume":"14","author":"Trinchieri","year":"1993","journal-title":"Immunol Today"},{"key":"10.1016\/j.intimp.2011.05.008_bb1715","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1084\/jem.177.5.1505","article-title":"Recombinant interleukin 12 cures mice infected with Leishmania major","volume":"177","author":"Heinzel","year":"1993","journal-title":"J Exp Med"},{"key":"10.1016\/j.intimp.2011.05.008_bb1720","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1084\/jem.177.6.1797","article-title":"Resolution of cutaneous leishmaniasis: interleukin 12 initiates a protective Th1 immune response","volume":"177","author":"Sypek","year":"1993","journal-title":"J Exp Med"},{"key":"10.1016\/j.intimp.2011.05.008_bb1725","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1093\/intimm\/5.9.1119","article-title":"Dendritic cells and macrophages are required for Th1 development of CD4+ T cells from alpha-beta-TCR transgenic mice: IL-12 substitution for macrophages to stimulate IFN-\u03b3 production is IFN-g dependent","volume":"5","author":"Macatonia","year":"1993","journal-title":"Int Immunol"},{"key":"10.1016\/j.intimp.2011.05.008_bb1730","doi-asserted-by":"crossref","first-page":"5914","DOI":"10.1073\/pnas.90.13.5914","article-title":"Interleukin 4 suppresses interleukin 2 and interferon-\u03b3 production by na\u00efve T cells stimulated by accessory cell-dependent receptor engagement","volume":"90","author":"Tanaka","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.intimp.2011.05.008_bb1735","doi-asserted-by":"crossref","first-page":"5771","DOI":"10.4049\/jimmunol.168.11.5771","article-title":"The role of IL-12 in maintaining resistance to Leishmania major","volume":"168","author":"Park","year":"2002","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.intimp.2011.05.008_bb1740","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1084\/jem.183.2.515","article-title":"Leishmania promastigotes selectively inhibit interleukin 12 induction in bone marrow-derived macrophages from susceptible and resistant mice","volume":"183","author":"Carrera","year":"1996","journal-title":"J Exp Med"},{"key":"10.1016\/j.intimp.2011.05.008_bb1745","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/(SICI)1521-4141(199802)28:02<687::AID-IMMU687>3.0.CO;2-N","article-title":"Dendritic cells, but not macrophages, produce IL-12 immediately following Leishmania donovani infection","volume":"28","author":"Gorak","year":"1988","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.intimp.2011.05.008_bb1750","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1084\/jem.188.8.1547","article-title":"Uptake of Leishmania major amastigotes results in activation and interleukin 12 release from murine skin derived dendritic cells: implications for the initiation of anti-Leishmania immunity","volume":"188","author":"Von Stebut","year":"1998","journal-title":"J Exp Med"},{"key":"10.1016\/j.intimp.2011.05.008_bb1755","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1002\/(SICI)1521-4141(199906)29:06<1803::AID-IMMU1803>3.0.CO;2-F","article-title":"Murine dendritic cells internalize Leishmania major promastigotes, produce IL-12p40 and stimulate primary T cell proliferation in vitro","volume":"29","author":"Konecny","year":"1999","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.intimp.2011.05.008_bb1760","doi-asserted-by":"crossref","first-page":"5858","DOI":"10.4049\/jimmunol.164.11.5858","article-title":"IL-12p70 production by Leishmania major-harboring human dendritic cells is a CD40\/CD40 ligand-dependent process","volume":"164","author":"Marovich","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/j.intimp.2011.05.008_bb1765","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1084\/jem.192.4.507","article-title":"Preformed membrane associated stores of interleukin (IL)-12 are a previously unrecognized source of bioactive IL-12 that is mobilized within minutes of contact with an intracellular parasite","volume":"192","author":"Quinones","year":"2000","journal-title":"J Exp Med"},{"key":"10.1016\/j.intimp.2011.05.008_bb1770","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1093\/intimm\/10.11.1593","article-title":"High-level IL-12 production by human dendritic cells requires two signals","volume":"10","author":"Snijders","year":"1998","journal-title":"Int Immunol"},{"key":"10.1016\/j.intimp.2011.05.008_bb1775","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1365-3083.1995.tb03527.x","article-title":"Subpopulations of T lymphocytes in the peripheral blood, dermal lesions and lymph nodes of post kala-azar dermal leishmaniasis patients","volume":"41","author":"Ghosh","year":"1995","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.intimp.2011.05.008_bb1780","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/00034983.1988.11812205","article-title":"Modulation of the cell-mediated immune response in kala-azar and post-kala-azar dermal leishmaniasis in relation to chemotherapy","volume":"82","author":"Neogy","year":"1988","journal-title":"Ann Trop Med Parasitol"},{"issue":"6","key":"10.1016\/j.intimp.2011.05.008_bb1785","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1086\/516482","article-title":"Endogenous interleukin-12 regulates acquired resistance in experimental visceral leishmaniasis","volume":"175","author":"Murray","year":"1997","journal-title":"J Infect Dis"},{"key":"10.1016\/j.intimp.2011.05.008_bb1790","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/bmb\/ldl003","article-title":"Current understandings on the immunology of leishmaniasis and recent developments in prevention and treatment","volume":"75\u201376","author":"Roberts","year":"2006","journal-title":"Br Med Bull"},{"key":"10.1016\/j.intimp.2011.05.008_bb1795","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1084\/jem.179.4.1367","article-title":"CD4+ effector cells default to the Th2 pathway in interferon gamma-deficient mice infected with Leishmania major","volume":"179","author":"Wang","year":"1994","journal-title":"J Exp Med"},{"key":"10.1016\/j.intimp.2011.05.008_bb1800","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.4049\/jimmunol.147.9.3149","article-title":"IFN-\u03b3 modulates the early development of Th1 & Th2 response in murine model of cutaneous leishmaniasis","volume":"147","author":"Scott","year":"1991","journal-title":"J Immunol"},{"key":"10.1016\/j.intimp.2011.05.008_bb1805","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1084\/jem.181.3.961","article-title":"Mice from a genetically resistant background lacking the interferon gamma receptor are susceptible to infection with Leishmania major but mount a polarized T helper cell 1-type CD4+ T cell response","volume":"181","author":"Swihart","year":"1995","journal-title":"J Exp Med"},{"key":"10.1016\/j.intimp.2011.05.008_bb1810","doi-asserted-by":"crossref","first-page":"266","DOI":"10.4049\/jimmunol.143.1.266","article-title":"Administration of monoclonal anti-IFN-gamma antibodies in vivo abrogates natural resistance of C3H\/HeN mice to infection with Leishmania major","volume":"143","author":"Belosevic","year":"1989","journal-title":"J Immunol"},{"key":"10.1016\/j.intimp.2011.05.008_bb1815","doi-asserted-by":"crossref","first-page":"768","DOI":"10.4049\/jimmunol.153.2.768","article-title":"Role and effect of TNF-\u03b1 in experimental visceral leishmaniasis","volume":"153","author":"Tumang","year":"1994","journal-title":"J Immunol"},{"key":"10.1016\/j.intimp.2011.05.008_bb1820","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.4049\/jimmunol.166.6.4012","article-title":"Rapidly fatal leishmaniasis in resistant C57BL\/6 mice lacking TNF","volume":"166","author":"Wilhelm","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.intimp.2011.05.008_bb1825","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1128\/IAI.59.8.2839-2842.1991","article-title":"Role of tumor necrosis factor in macrophage leishmanicidal activity in vitro and resistance to cutaneous leishmaniasis in vivo","volume":"59","author":"Theodos","year":"1991","journal-title":"Infect Immun"},{"issue":"3","key":"10.1016\/j.intimp.2011.05.008_bb1830","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.vaccine.2009.10.053","article-title":"Innate immune defense in visceral leishmaniasis: cytokine mediated protective role by allogenic effector cell","volume":"28","author":"Manna","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2011.05.008_bb1835","first-page":"570","article-title":"Tumour necrosis factor (TNF alpha) in leishmaniasis. I. TNF alpha mediates host protection against cutaneous leishmaniasis","volume":"69","author":"Liew","year":"1990","journal-title":"Immunology"},{"key":"10.1016\/j.intimp.2011.05.008_bb1840","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/0092-8674(89)90676-4","article-title":"The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection","volume":"56","author":"Kindler","year":"1989","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2011.05.008_bb1845","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1084\/jem.174.5.1209","article-title":"Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes","volume":"174","author":"de Waal Malefyt","year":"1991","journal-title":"J Exp Med"},{"key":"10.1016\/j.intimp.2011.05.008_bb1850","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1590\/S0100-879X1998000100020","article-title":"Cytokine profile and pathology in human leishmaniasis","volume":"31","author":"Ribeiro-de-Jesus","year":"1998","journal-title":"Braz J Med Biol Res"},{"key":"10.1016\/j.intimp.2011.05.008_bb1855","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1574-695X.2007.00311.x","article-title":"Immune response to Leishmania: paradox rather than paradigm","volume":"51","author":"Tripathi","year":"2007","journal-title":"FEMS Immunol Med Microbiol"},{"issue":"1","key":"10.1016\/j.intimp.2011.05.008_bb1860","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1172\/JCI116570","article-title":"Interleukin 10 production correlates with pathology in human Leishmania donovani infections","volume":"92","author":"Ghalib","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1016\/j.intimp.2011.05.008_bb1865","doi-asserted-by":"crossref","first-page":"5949","DOI":"10.4049\/jimmunol.152.12.5949","article-title":"Restoration of IFN-gamma production and lymphocyte proliferation in visceral leishmaniasis","volume":"152","author":"Carvalho","year":"1994","journal-title":"J Immunol"},{"key":"10.1016\/j.intimp.2011.05.008_bb1870","doi-asserted-by":"crossref","first-page":"8676","DOI":"10.1073\/pnas.89.18.8676","article-title":"Interleukin 10 inhibits macrophage microbicidal activity by blocking the endogenous production of tumor necrosis factor alpha required as a costimulatory factor for interferon gamma induced activation","volume":"89","author":"Oswald","year":"1992","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.intimp.2011.05.008_bb1875","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1084\/jem.178.3.1041","article-title":"Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor\/IL-12 synthesis in accessory cells","volume":"178","author":"D'Andrea","year":"1993","journal-title":"J Exp Med"},{"issue":"3","key":"10.1016\/j.intimp.2011.05.008_bb1880","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.4049\/jimmunol.151.3.1224","article-title":"IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression","volume":"151","author":"Ding","year":"1993","journal-title":"J Immunol"},{"key":"10.1016\/j.intimp.2011.05.008_bb1885","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1002\/eji.1830250913","article-title":"Macrophage T cell interaction in experimental visceral leishmaniasis: failure to express co-stimulatory molecules on Leishmania-infected macrophages and its implication in the suppression of cell-mediated immunity","volume":"25","author":"Saha","year":"1995","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.intimp.2011.05.008_bb1890","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1084\/jem.180.1.211","article-title":"Interleukin 12 synergizes with B7\/CD28 interaction in inducing efficient proliferation and cytokine production of human T cells","volume":"180","author":"Kubin","year":"1994","journal-title":"J Exp Med"},{"key":"10.1016\/j.intimp.2011.05.008_bb1895","doi-asserted-by":"crossref","first-page":"4623","DOI":"10.4049\/jimmunol.154.9.4623","article-title":"Interleukin-12 enhances Th1-type responses in human Leishmania donovani infections","volume":"154","author":"Ghalib","year":"1995","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.intimp.2011.05.008_bb1900","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.imlet.2005.01.009","article-title":"T helper (h)1\/Th2 and Leishmania: paradox rather than paradigm","volume":"99","author":"Alexander","year":"2005","journal-title":"Immunol Lett"},{"key":"10.1016\/j.intimp.2011.05.008_bb1905","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.micpath.2004.11.002","article-title":"Immunopathogenesis of infection with the visceralizing Leishmania species","volume":"38","author":"Wilson","year":"2005","journal-title":"Microb Pathog"},{"issue":"12","key":"10.1016\/j.intimp.2011.05.008_bb1910","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1128\/IAI.58.12.3863-3870.1990","article-title":"Patterns of cytokine secretion in murine leishmaniasis: correlation with disease progression or resolution","volume":"58","author":"Boom","year":"1990","journal-title":"Infect Immun"},{"key":"10.1016\/j.intimp.2011.05.008_bb1915","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/eji.1830190712","article-title":"Macrophage activation by interferon-\u03b3 from host protective T cell is inhibited by interleukin (IL) 3 and IL 4 produced by disease promoting T cells in leishmaniasis","volume":"19","author":"Liew","year":"1989","journal-title":"Eur J Immunol"},{"issue":"3","key":"10.1016\/j.intimp.2011.05.008_bb1920","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1084\/jem.184.3.1127","article-title":"IL-4-deficient BALB\/c mice resist infection with Leishmania major","volume":"184","author":"Kopf","year":"1996","journal-title":"J Exp Med"},{"key":"10.1016\/j.intimp.2011.05.008_bb1925","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/0090-1229(90)90038-R","article-title":"Determinants of the immune response in visceral leishmaniasis: evidence for predominance of endogenous interleukin 4 over interferon gamma production","volume":"57","author":"Zwingenberger","year":"1990","journal-title":"Clin Immunol Immunopathol"},{"key":"10.1016\/j.intimp.2011.05.008_bb1930","doi-asserted-by":"crossref","first-page":"522","DOI":"10.4269\/ajtmh.1997.56.522","article-title":"Circulating T helper 1 (Th1) cell- and Th2 cell-associated cytokines in Indian patients with visceral leishmaniasis","volume":"56","author":"Sundar","year":"1997","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.intimp.2011.05.008_bb1935","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1086\/517817","article-title":"Splenic cytokine responses in Indian kala-azar before and after treatment","volume":"177","author":"Kenney","year":"1998","journal-title":"J Infect Dis"},{"key":"10.1016\/j.intimp.2011.05.008_bb1940","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.4049\/jimmunol.140.8.2721","article-title":"Suppression of IL-2 production by cryopreserved peripheral blood mononuclear cells from patients with active visceral leishmaniasis in Sicily","volume":"140","author":"Cillari","year":"1988","journal-title":"J Immunol"},{"key":"10.1016\/j.intimp.2011.05.008_bb1945","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0035-9203(01)90344-X","article-title":"Interleukin-13 in Iranian patients with visceral leishmaniasis: relationship to other Th2 and Th1 cytokines","volume":"95","author":"Babaloo","year":"2001","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.intimp.2011.05.008_bb1950","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1006\/cyto.2000.0694","article-title":"IL-10 and IL-12 are the main regulatory cytokines in visceral leishmaniasis","volume":"12","author":"Bacellar","year":"2000","journal-title":"Cytokine"},{"key":"10.1016\/j.intimp.2011.05.008_bb1955","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1128\/IAI.68.4.1773-1780.2000","article-title":"Interleukin-4 receptor alphadeficient BALB\/c mice show an unimpaired T helper 2 polarization in response to Leishmania major infection","volume":"68","author":"Mohrs","year":"2000","journal-title":"Infect Immun"},{"key":"10.1016\/j.intimp.2011.05.008_bb1960","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/ni725","article-title":"IL-4 instructs TH1 responses and resistance to Leishmania major in susceptible BALB\/c mice","volume":"2","author":"Biedermann","year":"2001","journal-title":"Nat Immunol"},{"key":"10.1016\/j.intimp.2011.05.008_bb1965","doi-asserted-by":"crossref","first-page":"4804","DOI":"10.1128\/IAI.71.8.4804-4807.2003","article-title":"Both interleukin-4 (IL-4) and IL-4 receptor alpha signaling contribute to the development of hepatic granulomas with optimal antileishmanial activity","volume":"71","author":"Stager","year":"2003","journal-title":"Infect Immun"},{"key":"10.1016\/j.intimp.2011.05.008_bb1970","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1038\/nm933","article-title":"Natural antibodies and complement are endogenous adjuvants for vaccine-induced CD8+ T-cell responses","volume":"9","author":"Stager","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.intimp.2011.05.008_bb1975","doi-asserted-by":"crossref","first-page":"3855","DOI":"10.4049\/jimmunol.137.12.3855","article-title":"Transforming growth factor \u03b2 is an important immunomodulatory protein for human B lymphocytes","volume":"137","author":"Kehrl","year":"1986","journal-title":"J Immunol"},{"key":"10.1016\/j.intimp.2011.05.008_bb1980","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1084\/jem.163.5.1037","article-title":"Production of transforming growth factor \u03b2 by human T lymphocytes and its potential role in the regulation of T cell growth","volume":"163","author":"Kehrl","year":"1986","journal-title":"J Exp Med"},{"key":"10.1016\/j.intimp.2011.05.008_bb1985","doi-asserted-by":"crossref","first-page":"940","DOI":"10.4049\/jimmunol.145.3.940","article-title":"Macrophage deactivating factor and transforming growth factors \u03b21, \u03b22, and \u03b23 inhibit induction of macrophage nitrogen oxide synthesis by IFN-\u03b3","volume":"145","author":"Ding","year":"1990","journal-title":"J Immunol"},{"key":"10.1016\/j.intimp.2011.05.008_bb1990","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/334260a0","article-title":"Deactivation of macrophages by transforming growth factor \u03b2","volume":"334","author":"Tsunawaki","year":"1988","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2011.05.008_bb1995","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S0169-4758(99)01562-8","article-title":"Maintaining the immunological balance in parasitic infections: a role for TGF-\u03b2?","volume":"16","author":"Omer","year":"2000","journal-title":"Parasitol Today"},{"key":"10.1016\/j.intimp.2011.05.008_bb2000","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1006\/bbrc.1995.1094","article-title":"Arginase induction by suppressors of nitric oxide synthesis (IL-4, IL-10 and PGE2) in murine bone marrow-derived macrophages","volume":"206","author":"Corraliza","year":"1995","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.intimp.2011.05.008_bb2005","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1084\/jem.180.5.1587","article-title":"Transforming growth factor-\u03b2: the good, the bad and the ugly","volume":"180","author":"Wahl","year":"1994","journal-title":"J Exp Med"},{"key":"10.1016\/j.intimp.2011.05.008_bb2010","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1084\/jem.178.2.605","article-title":"Mechanisms of suppression of macrophage nitric oxide release by transforming growth factor \u03b2","volume":"178","author":"Vodovotz","year":"1993","journal-title":"J Exp Med"},{"key":"10.1016\/j.intimp.2011.05.008_bb2015","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1084\/jem.180.3.783","article-title":"Tissue expression of inducible nitric oxide synthase is closely associated with resistance to Leishmania major","volume":"180","author":"Stenger","year":"1994","journal-title":"J Exp Med"},{"key":"10.1016\/j.intimp.2011.05.008_bb2020","doi-asserted-by":"crossref","first-page":"5320","DOI":"10.4049\/jimmunol.154.10.5320","article-title":"IL-12 is required for natural killer cell activation and subsequent T helper 1 cell development in experimental leishmaniasis","volume":"154","author":"Scharton-Kersten","year":"1995","journal-title":"J Immunol"},{"key":"10.1016\/j.intimp.2011.05.008_bb2025","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.1073\/pnas.90.8.3442","article-title":"Transforming growth factor \u03b2 as a virulence mechanism for Leishmania braziliensis","volume":"90","author":"Barral","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.intimp.2011.05.008_bb2030","first-page":"947","article-title":"Transforming growth factor \u03b2 in human cutaneous leishmaniasis","volume":"147","author":"Barral","year":"1995","journal-title":"Am J Pathol"},{"key":"10.1016\/j.intimp.2011.05.008_bb2035","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1126\/science.1636092","article-title":"Transforming growth factor \u03b2 in Leishmania infection: a parasite escape mechanism","volume":"257","author":"Barral-Netto","year":"1992","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.intimp.2011.05.008_bb2040","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1128\/IAI.66.3.1233-1236.1998","article-title":"Transforming growth factor \u03b2 and immunosuppression in experimental visceral leishmaniasis","volume":"66","author":"Rodrigues","year":"1998","journal-title":"Infect Immun"},{"key":"10.1016\/j.intimp.2011.05.008_bb2045","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.4049\/jimmunol.170.5.2613","article-title":"Activation of TGF-{beta} by Leishmania chagasi: importance for parasite survival in macrophages","volume":"170","author":"Gantt","year":"2003","journal-title":"J Immunol"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576911002190?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576911002190?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T03:40:01Z","timestamp":1686109201000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576911002190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":409,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["S1567576911002190"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2011.05.008","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]}}}